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• ErbB1 inhibitors reverse hypersensitivity in neuropathic pain models, as clinically 45 
• Nociceptors in DRG selectively express ErbB1 and ErbB2 but not ErbB3 or ErbB4 46 
• ErbB1 drives Akt- /AS160-dependent trafficking of nociceptor Na+ and Ca2+ channels 47 
• ErbB1- and Akt-inhibitors prevent channel trafficking and hypersensitivity  48 




Abstract  1 
 2 
Effective analgesic treatment for neuropathic pain remains an unmet need, so 3 
previous evidence that epidermal growth factor receptor inhibitors (EGFRIs) provide 4 
unexpected rapid pain relief in a clinical setting points to a novel therapeutic 5 
opportunity. The present study utilises rodent models to address the cellular and 6 
molecular basis for the findings, focusing on primary sensory neurons because clinical 7 
pain relief is provided not only by small molecule EGFRIs, but also by the anti-EGFR 8 
antibodies cetuximab and panitumumab, which are unlikely to access the central 9 
nervous system in therapeutic concentrations. We report robust, rapid and dose-10 
dependent analgesic effects of EGFRIs in two neuropathic pain models, matched by 11 
evidence with highly selective antibodies that expression of the EGFR (ErbB1 protein) 12 
is limited to small nociceptive afferent neurons. As other ErbB family members can 13 
heterodimerise with ErbB1, we investigated their distribution, showing consistent co-14 
expression of ErbB2 but not ErbB3 or ErbB4, with ErbB1 in cell bodies of nociceptors, 15 
as well as providing evidence for direct molecular interaction of ErbB1 with ErbB2 in 16 
situ. Co-administration of selective ErbB1 and ErbB2 inhibitors produced clear 17 
evidence of greater-than-additive, synergistic analgesia; highlighting the prospect of a 18 
unique new combination therapy in which enhanced efficacy could be accompanied 19 
by minimisation of side-effects. Peripheral (intraplantar) administration of EGF elicited 20 
hypersensitivity only following nerve injury and this was reversed by local co-21 
administration of selective inhibitors of either ErbB1 or ErbB2. Investigating how ErbB1 22 
is activated in neuropathic pain, we found evidence for a role of Src tyrosine kinase, 23 
which can be activated by signals from inflammatory mediators, chemokines and 24 
cytokines during neuroinflammation. Considering downstream consequences of 25 
ErbB1 activation in neuropathic pain, we found direct recruitment to ErbB1 of an 26 
adapter for PI 3-kinase and Akt signalling together with clear Akt activation and robust 27 
analgesia from selective Akt inhibitors. The known Akt target and regulator of vesicular 28 
trafficking, AS160 was strongly phosphorylated at a perinuclear location during 29 
neuropathic pain in an ErbB1-, ErbB2- and Akt-dependent manner, corresponding to 30 
clustering and translocation of an AS160-partner, the vesicular chaperone, LRP1.  31 
Exploring whether neuronal ion channels that could contribute to hyperexcitability 32 
might be transported by this vesicular trafficking pathway we were able to identify 33 
Nav1.9, (Nav1.8) and Cav1.2 moving towards the plasma membrane or into proximal 34 
axonal locations – a process prevented by ErbB1 or Akt inhibitors. Overall these 35 
findings newly reveal both upstream and downstream signals to explain how ErbB1 36 
can act as a signalling hub in neuropathic pain models and identify the trafficking of 37 
key ion channels to neuronal subcellular locations likely to contribute to 38 
hyperexcitability. The new concept of combined treatment with ErbB1 plus ErbB2 39 
blockers is mechanistically validated as a promising strategy for the relief of 40 
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Introduction  1 
 2 
Chronic hypersensitive pain states, especially those due to nerve injury 3 
(neuropathic pain) are difficult to treat with current medications, which show limited 4 
efficacy and frequently treatment-limiting side effects (Finnerup, Sindrup et al. 2010). 5 
There is a clear unmet need to develop new, safe and efficacious analgesics for 6 
neuropathic pain through novel targeting strategies. One such approach originated 7 
from our serendipitous observation of remarkable pain relief in a rectal cancer patient 8 
treated with the anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, 9 
despite tumour progression (Kersten and Cameron 2012), which initiated a reverse-10 
translational programme to elucidate the role of the EGFR in pain processing. Clinical 11 
follow-up studies on a small case series and then a larger study of patients with 12 
neuropathic pain of different origins (both cancer and non-cancer) showed similarly 13 
promising results (80% clinically meaningful response) with cetuximab, panitumumab 14 
and the small molecule EGFR inhibitors, gefitinib and erlotinib (Kersten, Cameron et 15 
al. 2013, Kersten, Cameron et al. 2015). A small-scale randomised proof-of-concept 16 
trial of cetuximab in neuropathic pain patients (nerve compression and complex 17 
regional pain syndrome), corroborated the idea of a clinically meaningful analgesic 18 
signal (Kersten, Cameron et al. 2019). Importantly, many of the patients responding 19 
to EGFR inhibitors had pain that had proved refractory to all other interventions, 20 
emphasizing the potential of this novel strategy. Some mechanistic insight arises from 21 
the efficacy displayed by cetuximab and panitumumab (which are unlikely to penetrate 22 
the blood-brain barrier in therapeutic concentrations) and therefore implicates primary 23 
sensory afferents as a likely site of action. 24 
 Independent support for the idea of EGFR involvement in chronic pain has 25 
come from molecular genetics analysis (Martin, Smith et al. 2017, Verma, Khoury et 26 
al. 2020) of patients with temporomandibular disorders – a group of conditions 27 
associated with chronic pain from joint, muscle or central origins (Cairns 2010). A 28 
number of single nucleotide polymorphisms (SNPs) in the genes for epiregulin (an 29 
EGFR ligand) and EGFR showed significant differential association with TMD patient 30 
and control groups (Martin, Smith et al. 2017, Verma, Khoury et al. 2020). The minor 31 
allele of the epiregulin SNP most strongly associated with reduced odds of chronic 32 
TMD was matched to lower epiregulin mRNA levels in leukocytes (Martin, Smith et al. 33 
2017). However, the minor allele was also associated with increased numbers of acute 34 
pain sites in TMD patients (Verma, Khoury et al. 2020). Rodent chronic pain models 35 
have provided further support for a role of the EGFR in pain processing. The 36 
hypersensitivity due to nerve injury, inflammation or direct compression injury to DRG 37 
(CCD) was attenuated by EGFR-selective inhibitors (although across a range of 38 
potencies) and also (in the case of CCD) by EGFR siRNA (Martin, Smith et al. 2017, 39 
Wang, Liu et al. 2019). Furthermore, mice expressing a constitutively activating EGFR 40 
mutation show enhanced responses to formalin, while Drosophila larvae with EGFR 41 
knockdown in peripheral nociceptors display impaired thermal nociception (Martin, 42 
Smith et al. 2017). 43 
 4 
The EGFR (ErbB1) is one of a family of 4 receptor tyrosine kinases (RTKs), 1 
which display sequence homology and a common structural organisation (Olayioye, 2 
Neve et al. 2000). ErbB2 is thought to lack a physiological ligand yet act as the 3 
preferred heterodimerisation partner for all other ErbB receptors (Graus-Porta, Beerli 4 
et al. 1997, Tzahar, Pinkas-Kramarski et al. 1997) and can enable constitutive 5 
functional activity (Garrett, McKern et al. 2003), while ErbB3 has ligands but displays 6 
minimal levels of tyrosine kinase catalytic activity (around 1000-fold less than ErbB1) 7 
(Shi, Telesco et al. 2010). The functional importance of ErbB1:ErbB2 heterodimers is 8 
emphasised, for example, by the elevated basal phosphorylation of both ErbB1 and 9 
ErbB2 in co-transfected cells and the potent inhibition of ErbB2-overexpressing 10 
tumour and cell line proliferation by highly selective ErbB1 inhibitors (Moasser, Basso 11 
et al. 2001).  ErbB dimerisation generally comes about as a result of ligand-induced 12 
conformational changes stabilising an extended configuration of extracellular domains 13 
(Dawson, Berger et al. 2005). The chimeric human/murine monoclonal antibody, 14 
cetuximab (Kim, Khuri et al. 2001, Harding and Burtness 2005) binds to an 15 
extracellular domain of ErbB1 that partly occludes the ligand binding site and also 16 
inhibits transition to the extended configuration necessary for dimerisation (Li, Schmitz 17 
et al. 2005, Berger, Krengel et al. 2011) but importantly results in down-regulation of 18 
EGFR expression (Perez-Torres, Guix et al. 2006). Although the classical paradigm 19 
for ErbB receptor activation centres on ligand-induced initiation of dimerisation, there 20 
is evidence for ligand-independent formation of homo- and hetero-dimers (including 21 
ErbB1:ErbB2) and in some cases for their initial assembly in the endoplasmic 22 
reticulum (Verveer, Wouters et al. 2000, Moriki, Maruyama et al. 2001, Sawano, 23 
Takayama et al. 2002, Yu, Sharma et al. 2002, Kumagai, Katsumata et al. 2003, Tao 24 
and Maruyama 2008, Junttila, Akita et al. 2009). 25 
ErbB receptors undergo constant internalisation, intracellular shuttling and 26 
recycling (Wiley 2003). Although ErbB1 is predominantly localised at the cell surface 27 
in fibroblasts, other cell types maintain large intracellular pools of unliganded receptor 28 
(Burke and Wiley 1999, Kim, Khuri et al. 2001). In the case of cetuximab binding to 29 
ErbB1, the internalised complex is resistant to dissociation in the acidified environment 30 
of endosomes and is therefore targeted for lysosomal degradation rather than 31 
recycling, thereby quickly depleting the shuttling pool of ErbB1 receptor protein 32 
(Jimeno, Rubio-Viqueira et al. 2005, Li, Schmitz et al. 2005). Neuronal ErbB1 33 
expression has been reported in both the CNS and dorsal root ganglia (DRG) (Gomez-34 
Pinilla, Knauer et al. 1988, Ferrer, Alcantara et al. 1996, Xian and Zhou 1999). In DRG, 35 
expression has been reported to be preferentially in smaller neurons (Huerta, Diaz-36 
Trelles et al. 1996, Xian and Zhou 1999), whereas other studies have suggested a 37 
widespread neuronal localisation (Andres, Meyer et al. 2010, Martin, Smith et al. 2017) 38 
or preferential expression in medium/large myelinated neurons and minimal co-39 
expression with markers of small unmyelinated neurons (Wang, Liu et al. 2019). Some 40 
studies also report ErbB1 expression in glial cells within DRG (Andres, Meyer et al. 41 
2010, Wang, Liu et al. 2019). Expression of other ErbB family members has also been 42 
reported in DRG neurons (Pearson and Carroll 2004). 43 
 5 
ErbB receptors achieve diverse signalling outcomes by trans- or 1 
autophosphorylation of Tyr residues in their intracellular carboxy-terminal domains, 2 
which act as high affinity docking sites for various signalling and adapter proteins 3 
(Olayioye, Neve et al. 2000). ErbB1 autophosphorylation at Tyr1068 primarily leads to 4 
the recruitment of signalling adapters, Grb2 (to regulate the ERK MAP kinase 5 
pathway) and Gab1 (to enable PI 3-kinase binding and activation, then downstream 6 
activation of Akt) (Lowenstein, Daly et al. 1992, Downward 1994, Holgado-Madruga, 7 
Emlet et al. 1996, Rodrigues, Falasca et al. 2000, Mattoon, Lamothe et al. 2004, Cao, 8 
Huang et al. 2009). In endothelial cells stably transfected with ErbB1 or ErbB1 plus 9 
ErbB2, there is evidence for ligand-independent activation as shown by significant 10 
basal phosphorylation of ErbB1, ErbB2 and ERK (Berger, Krengel et al. 2011). In this 11 
model, cetuximab markedly reduced not only EGF-induced responses, but also basal, 12 
unstimulated ERK phosphorylation, clearly impacting on ligand-independent 13 
downstream signalling from ErbB1/2.  14 
In view of the clinical findings pointing to the potential of EGFR inhibition as a 15 
strategy for alleviation of chronic hypersensitive pain, we sought to corroborate this in 16 
a controlled laboratory setting and explore some of the underlying mechanisms. 17 
Although the humanised/human monoclonal antibodies, cetuximab and panitumumab, 18 
would not be useful tools in rodent studies due to immune incompatibility, many small 19 
molecule inhibitors of different ErbB family receptors have been developed because 20 
of their therapeutic potential in oncology (Roskoski 2014, Kavuri, Jain et al. 2015). A 21 
number of these tyrosine kinase inhibitors (TKIs) are very highly selective for particular 22 
ErbB receptors, against other ErbB family members and panels of other protein 23 
kinases (Fabian, Biggs et al. 2005, Anastassiadis, Deacon et al. 2011, Davis, Hunt et 24 
al. 2011).  25 
 26 
 27 
Material and Methods 28 
 29 
Animals 30 
All animal breeding, maintenance and experimental procedures complied with 31 
ARRIVE guidelines and were carried out in accordance with the UK Animals (Scientific 32 
Procedures) Act 1986, with approval from the University of Edinburgh’s Local Ethical 33 
Review Board. Animals were housed under a 12h light-dark cycle and given access 34 
to food and water ad libitum.  Most experiments were carried out on adult Sprague-35 
Dawley rats (200-350g in weight, which were male unless otherwise indicated). The 36 
sciatic nerve chronic constriction injury (CCI) preparation was used as a model of 37 
chronic neuropathic pain in rats (Bennett and Xie 1988). Animals were anaesthetised 38 
with a 4% isoflurane/oxygen mixture (Zeneca, Cheshire, UK) before exposure of the 39 
sciatic nerve, proximal to the trifurcation at mid-thigh level. Four loose ligatures of 40 
chromic catgut (SMI AG, Hunningen, Belgium) were tied around the nerve, separated 41 
by 1mm. CCI rats consistently developed ipsilateral thermal reflex hypersensitivity, 42 
which peaked between days 8 and 12 post-surgery, when experiments were carried 43 
out. Some experiments were carried out in adult male C57/Bl6J mice (25-35g in 44 
 6 
weight), using an oxaliplatin model of chemotherapy-induced peripheral neuropathy 1 
(CIPN) (Zhao, Isami et al. 2012). Oxaliplatin (Abcam) in 5% glucose vehicle was 2 
injected intraperitoneally (under light isoflurane anaesthesia) at a dose of 7mg/kg 3 
(100µl/mouse) and experiments carried out 3-7days later when mechanical 4 
hypersensitivity was fully developed.  5 
 6 
Quantitative sensory testing in vivo 7 
Mechanical and thermal nociceptive sensitivity were assessed using standard 8 
behavioural tests, during which, the investigator was blinded to drug treatment. 9 
Mechanical nociception was assessed as Paw Withdrawal Threshold (PWT; in g) from 10 
force-calibrated von Frey nylon filaments (Stoelting, Illinois). Nociceptive heat 11 
sensitivity was measured as Paw Withdrawal Latency (PWL; in sec) using Hargreaves’ 12 
infrared apparatus (Linton Instrumentation), set to a maximum temperature of 52oC 13 
and a cut-off time of 20sec. Testing was always separated by at least 5min to avoid 14 
sensitisation of responses. Nociceptive cold sensitivity was measured as Suspended 15 
Paw Elevation Time using a shallow water bath at the temperature of iced water (~4oC) 16 
(Garry, Moss et al. 2003). Animals were initially habituated to the sensory testing 17 
environments to establish consistent responses.  18 
 19 
Drug administration in vivo 20 
Small molecule agents were obtained from MedChem Express, Selleckchem, 21 
Key Organics or Axon MedChem. Murine EGF, purified from submaxilliary gland and 22 
recombinant human neuregulin1-b1 EGF domain (NRG1) were obtained from Sigma-23 
Aldrich and R & D Systems, respectively. For intraperitoneal administration (200µl/rat 24 
and 100µl/mouse) agents were dissolved in 10% dimethylsulphoxide, 40% 25 
polyethylene glycol-400 and 50% propylene glycol. For intraplantar administration 26 
(50µl/rat) agents were dissolved in normal saline with 0.3% dimethylsulphoxide. 27 
Vehicle controls showed no discernible change in pain-associated behavioural 28 
responses. Doses of pharmacological agents were selected on the basis of those 29 
showing clear efficacy/target coverage (producing at least 80-90% maximal effects) in 30 
literature reports, wherever possible, or their reported potency in vitro compared to 31 
that of the benchmark, erlotinib.  32 
 33 
Immunofluorescence histochemistry 34 
DRGs from spinal segments L4-6 were dissected, rapidly embedded in cryo-35 
sectioning medium (Thermo Scientific) and frozen on dry ice. 18µm sections were cut 36 
by cryostat and mounted onto poly-L-lysine coated slides (Thermo Scientific). Sections 37 
were washed in Tris-Buffered Saline (TBS) pH7.60 and then incubated for 1h at room 38 
temperature in blocking buffer (10% normal donkey serum, 4% fish skin gelatin, 0.2% 39 
Triton X-100 in TBS) prior to overnight incubation at 4°C with a combination of primary 40 
antibodies in buffer (4% normal donkey serum, 4% fish skin gelatin and 0.2% Triton 41 
X-100 in TBS). The primary antibodies used are listed in Table 1. Sections were 42 
washed in TBS and incubated for 1h at room temperature with a combination of 43 
 7 
extensively cross-adsorbed, fluorescent secondary antibodies or Alexa Fluor-488 1 
conjugated isolectin IB4 (Invitrogen; I21411; 1:3000) in buffer (4% normal donkey 2 
serum, 4% fish skin gelatin in TBS). Donkey anti-mouse, rabbit, chicken or guinea pig 3 
secondary antibodies, labelled with 633/647, 568, 488 or 405 nm-emitting 4 
fluorophores in appropriate permutations, and all highly cross-adsorbed against other 5 
relevant species, were obtained from Biotium via Sigma-Aldrich and were used at a 6 
dilution of 1:600. Sections were washed three further times in TBS and then mounted 7 
in ProLong® Gold Antifade (Life Technologies). Standard primary antibody omission 8 
or blocking peptide controls, wherever possible, confirmed that non-specific staining 9 
was minimal. Both concentration-dependence of staining and association with 10 
peripherin-positive or NF-200-positive cellular profiles, where appropriate, 11 
corroborated specificity.  12 
 13 
Confocal microscopy and image analysis 14 
Fluorescence signals were acquired using a Nikon A1R confocal microscope 15 
at 1024 × 1024 pixel size frame, 12 bits per pixel images, with a pinhole size 1AU 16 
calculated for 488, using objectives 10X Plan Fluor/NA0.3, 20X Plan Apo VC/NA 0.8, 17 
or 60X Plan Apo VC/NA1.4 (oil immersion). In all cases, emissions for each 18 
fluorophore were obtained sequentially to avoid channel bleed-through. Z-stacks were 19 
acquired covering the whole thickness of each section at a low power magnification 20 
(acquired with 10X or 20X objectives; 5µm and 2µm step size between planes) and 21 
maximum intensity projections were generated using ImageJ/Fiji. All cells positive for 22 
markers of interest were blind-counted manually (using ImageJ/Fiji software plugin), 23 
usually versus ErbB1 or peripherin across the whole section in each case. Mean 24 
percentage expression values were generated over sections from at least 4 separate 25 
animals. Antigen distribution within single cells (collected at a high power with optical 26 
zoom at 0.09x0.09 pixel size) was analysed by measuring fluorescence intensity using 27 
Plot Profile tool in ImageJ/Fiji in single plane images (at the centre of each cell) and 28 
drawing a transect from the nuclear perimeter to the neuronal apex, that was then 29 
divided into 50 bins. Visualisation and three-dimensional reconstruction of images was 30 
performed using IMARIS (Bitplane). In the case of phospho-AS160 (Thr642), which 31 
was clustered tightly in a peri-nuclear location, only the proximal part of the transect 32 
(covering all the discernible fluorescence signal) was analysed by division into 33 
50x0.09µm bins starting at the nuclear perimeter, and fluorescence intensity recorded 34 
at each. In order to facilitate comparisons between transect profiles, values were 35 
normalised. If the mean intensity from the naïve and CCI datasets differed by more 36 
than 40% (as might be anticipated for newly evoked changes such as target 37 
phosphorylation or clustering of previously dispersed target proteins into aggregates), 38 
normalisation was carried out to the overall mean intensity of the entire data set. This 39 
enabled detection of changes in relative intensity as well as the location of any 40 
changes. If this value was less than 40% (consistent with simple redistribution of the 41 
target protein), normalisation was carried out to the mean for the individual cell 42 
sampled, which enabled clearer analysis of changes in fine subcellular localisation. 43 
 8 
Mean values were calculated generally across 8-9 individual cell transects originating 1 
from 4 separate animals in each case.  2 
 3 
Proximity Ligation Assay  4 
Evidence for in situ protein:protein interactions was obtained using the Duolink 5 
Proximity Ligation Assay (Sigma-Aldrich) (Fredriksson, Gullberg et al. 2002, 6 
Soderberg, Gullberg et al. 2006, Liu, Chen et al. 2013, Rivera-Oliver, Moreno et al. 7 
2019). Rabbit or mouse primary antibodies for potential protein partners are outlined 8 
in Table 1. Oligonucleotide-derivatised secondary antibody probes were donkey anti-9 
rabbit PLUS and donkey anti-mouse MINUS. Probe ligation, rolling circle amplification 10 
(RCA) and detection of the RCA product by Duolink Orange fluorophore (emission 11 
576nm) were all carried out according to the manufacturer’s instructions. An optimised 12 
procedure was developed to integrate conventional immunofluorescence 13 
counterstaining (with chicken anti-peripherin and donkey anti-chicken 488) into the 14 
protocol. 15 
 16 
Non-linear curve-fitting and statistical analysis 17 
All data analysis was carried out using GraphPad Prism. Non-linear curve-fitting 18 
used a sigmoidal dose-response (variable slope) model. Data in two-group format 19 
were analysed statistically by Student’s t-test.  Comparisons between more than two 20 
groups were made by One-Way ANOVA with Tukey’s or Dunnett’s test, or by Two-21 
Way ANOVA with Bonferroni’s test.  22 
  23 
Results  24 
 25 
ErbB1 involvement in hypersensitive pain behaviours and nociceptor activation 26 
following nerve injury 27 
Using the CCI neuropathic pain model, marked nociceptive hypersensitivity 28 
was observed in the ipsilateral (but not contralateral) hindlimb 8-12days following 29 
nerve injury. This was manifest as a reduction in Paw Withdrawal Threshold (PWT) 30 
from von Frey filament mechanical stimuli (Fig. 1A), a reduction in Paw Withdrawal 31 
Latency (PWL) from Hargreaves’ noxious thermal stimuli (Fig. 1B) and an increase in 32 
suspended paw elevation time from 4oC noxious cold stimuli (Fig. 1C). In each case, 33 
intraperitoneal administration of the highly selective inhibitor of ErbB1 tyrosine kinase 34 
function, erlotinib (Moyer, Barbacci et al. 1997) at a dose of 10mg/kg ip, produced 35 
marked rapid reversal of ipsilateral hypersensitivity, which was complete at peak effect 36 
and remained statistically significant for 140-160min. No discernible effects were 37 
observed on responses from the contralateral limb or from vehicle injection. This time 38 
course is consistent with evidence that plasma levels of erlotinib increase rapidly after 39 
administration and begin to decline steeply after around 2 hours (Pollack, Savage et 40 
al. 1999). The reversal of CCI-induced mechanical hypersensitivity by erlotinib was 41 
dose-dependent (with a statistically significant effect at as little as 1mg/kg and an IC50 42 
of 1.4 [1.3/1.5] mg/kg ip (mean [95% confidence interval]), (Table 2), corresponding to 43 
 9 
the dose range (100-150mg) found to provide effective pain relief in patients (Kersten, 1 
Cameron et al. 2015). The effect of erlotinib here was also replicated by further highly 2 
selective ErbB1 inhibitors, gefitinib (Moasser, Basso et al. 2001, Pedersen, Pedersen 3 
et al. 2005) and AG 1478 (Traxler, Green et al. 1999), with effects similar to erlotinib 4 
at corresponding doses (Table 2).  Reversal of nerve injury-induced mechanical 5 
hypersensitivity by erlotinib was similarly observed in female CCI rats (mean 6 
percentage reversal over 20-140min post-injection of 88.9±9.2%, n=4, p<0.01, at a 7 
dose of 10mg/kg ip). 8 
As most selective ErbB1 inhibitors are based around a common quinazoline 9 
core, we tested two further, structurally distinct selective agents, falnidamol (BIBX 10 
3182) (Solca, Baum et al. 2004) and EGFRi 324674 (Zhang, Liu et al. 2006). These 11 
contain distinct pyrimidopyrimidine and 4,6-substituted-pyrimidine cores, respectively 12 
and at appropriate doses they also produced robust reversal of hypersensitivity 13 
through 20-140min post-administration, respectively (n=4, in each case), confirming 14 
target-specific efficacy (Table 2). Similar results (demonstrating dose-dependence in 15 
each case) were observed in a mouse model of oxaliplatin-induced peripheral 16 
neuropathy (Zhao, Isami et al. 2012), with IC50 values [95% CI] of 3.2 [3.0/3.3] mg/kg 17 
ip for erlotinib, 2.4 [2.3/2.6] mg/kg ip for gefitinib and 3.0 [2.7/3.4] mg/kg ip for AG 1478 18 
(n=4 at 4-5 different doses in each case). In both rat CCI and mouse CIPN models, 19 
animals showed no discernible changes in general locomotion or motor function, or 20 
evidence of sedation, following administration of ErbB1 inhibitors. The doses of 21 
erlotinib producing analgesia in the neuropathic pain models here are similar to, or 22 
less than, those necessary to reverse EGF-induced autophosphorylation of ErbB1 in 23 
liver and tumour xenografts of athymic mice, consistent with appropriate target-24 
associated potency and coverage (Moyer, Barbacci et al. 1997, Pollack, Savage et al. 25 
1999). Repeated testing with erlotinib (10mg/kg ip) showed no significant attenuation 26 
of its ability to reverse CIPN-induced hypersensitivity over 7 daily treatments, similar 27 
to observations in the CCD (chronic DRG compression) model (Wang, Liu et al. 2019). 28 
In order to provide an unbiased biomarker of activity in nociceptive afferents we 29 
measured levels of phospho-CaM kinase IIa (Thr286) in DRG cells. This marker 30 
reflects Ca2+-dependent autophosphorylation of the enzyme to an autonomous form 31 
of the enzyme, but both activity and Thr286-phosphorylation diminish rapidly, within 32 
minutes, following stimulus removal (Lou, Lloyd et al. 1986, Schworer, Colbran et al. 33 
1986, Lengyel, Voss et al. 2004, Chang, Parra-Bueno et al. 2017). Figure 1D shows 34 
that phospho-CaMKII (Thr286) staining in small, peripherin-positive DRG cells was 35 
significantly increased ipsilateral to CCI and that this was almost completely reversed 36 
by erlotinib (10mg/kg ip, 1hr), indicating that CCI-induced activity in nociceptors is 37 
highly dependent on ErbB1 functional activity. 38 
 39 
ErbB1 is selectively localised in small, peripherin-positive DRG neurons  40 
As there was some disparity in previous reports over ErbB1 expression in 41 
subpopulations of DRG cells (Huerta, Diaz-Trelles et al. 1996, Xian and Zhou 1999, 42 
Andres, Meyer et al. 2010, Martin, Smith et al. 2017, Wang, Liu et al. 2019), we 43 
 10 
addressed this using extensively characterised ErbB1-specific antibodies. Figure 2A 1 
shows results using two antibodies documented to label ErbB1, but not other ErbB 2 
family members, revealing very high correlation between staining for ErbB1 and 3 
peripherin in small DRG cells that are likely to represent unmyelinated nociceptors 4 
(Goldstein, House et al. 1991, Fornaro, Lee et al. 2008). In DRG from naïve and CCI 5 
animals similarly, both ErbB1-specific antibodies stained 80-90% of peripherin-6 
positive small cells with minimal staining outwith this population. A third ErbB1 7 
antibody (mouse monoclonal 8G6.2); raised against a distinct intracellular epitope in 8 
ErbB1), confirmed these results, staining 84.8±1.2% of peripherin-positive DRG cells 9 
from naïve animals (CCI not tested; mean±SEM, n=4). In contrast, co-staining with the 10 
myelinated neuronal marker, NF-200 (Goldstein, House et al. 1991, Fornaro, Lee et 11 
al. 2008), the satellite glial cell marker, glutamine synthetase (Miller, Richards et al. 12 
2002) and the microglial/recruited macrophage marker, CD68 (Hu and McLachlan 13 
2003) was minimal (Fig. 2B). The pattern and levels of ErbB1 expression in DRG were 14 
not significantly altered following CCI. 15 
 Within the population of ErbB1-expressing small DRG cells, both presumed 16 
peptidergic C-fibres, staining for TRPV1 (Cavanaugh, Lee et al. 2009) and presumed 17 
non-peptidergic fibres, labelled with isolectin, IB4 (Dong, Han et al. 2001) were 18 
strongly represented, with 87.1±2.1% of TRPV1 (and peripherin)-positive cells, and 19 
88.6±2.1% of IB4 (and peripherin)-positive cells co-staining for ErbB1 (means±SEM, 20 
n=12). Similar values were found in CCI animals. These observations are consistent 21 
with the idea of ErbB1 playing an important role in nerve injury-induced 22 
hypersensitivity throughout the whole C-fibre nociceptor population. 23 
  As ErbB1 may heterodimerise with other ErbB family members (Olayioye, 24 
Neve et al. 2000), we also investigated the expression in DRG of ErbB2-4, using highly 25 
characterised, isotype-specific antibodies. We found ErbB2 to be widely and 26 
selectively expressed in small, peripherin-positive DRG cells, like ErbB1, with around 27 
90% of peripherin-positive cells expressing ErbB2 in both naïve and CCI animals (Fig. 28 
2C). Similar results were obtained for ErbB2 expression in ErbB1-positive cells (Fig. 29 
2C) and were confirmed with a second highly characterised ErbB2-specific antibody 30 
(mouse monoclonal, UMAB36) which showed staining in 76.2±6.3% and 78.5±4.4% 31 
of ErbB1-positive cells in naïve and CCI DRG, respectively (means±SEM, n=4). 32 
ErbB3- and ErbB4-specific antibodies showed minimal staining in DRG of naïve and 33 
CCI animals; with any staining rarely present in small, peripherin-positive cells, only 34 
3-8% of the population in each case (Fig. 2C). These observations suggested that 35 
ErbB2, in addition to ErbB1, could potentially represent an analgesic target in 36 
nociceptors; acting either independently or in concert with ErbB1 as a heterodimer; an 37 
idea supported by evidence that ErbB2 is the preferred heterodimerisation partner for 38 
all of the other ErbB family members (Graus-Porta, Beerli et al. 1997, Tzahar, Pinkas-39 
Kramarski et al. 1997).  40 
 41 
Functional evidence for a role of ErbB2 within C-fibre nociceptors in CCI-42 
induced hypersensitivity  43 
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 Using paw withdrawal threshold in the von Frey test, we showed that several 1 
ErbB2 blockers caused marked reversal of CCI-induced mechanical hypersensitivity. 2 
The highly selective ErbB2 inhibitors, mubritinib and tucatinib (ARRY-380), both of 3 
which show very low affinity for ErbB1 (Nagasawa, Mizokami et al. 2006, Moulder, 4 
Borges et al. 2017), each at a dose of 15mg/kg ip, produced marked reversal of CCI-5 
induced hypersensitivity, with complete reversal at peak in each case and both 6 
remaining statistically significant for 180min. The mean±SEM percentage reversals of 7 
hypersensitivity from 20-140min following administration were 91.5±4.7% (n=6) for 8 
mubritinib and 87.1±6.9% (n=4) for tucatinib, respectively (Fig. 3A). This validated 9 
ErbB2, in addition to ErbB1, as a potential analgesic target for neuropathic pain. Two 10 
dual inhibitors of both ErbB1 and ErbB2, lapatinib (a reversible blocker targeting 11 
ErbB1>ErbB2>ErbB4 (Rusnak, Lackey et al. 2001) at a dose of 20mg/kg ip, and 12 
afatinib (an irreversible covalent blocker targeting ErbB1>ErbB2>ErbB4 (Li, Ambrogio 13 
et al. 2008)) at a dose of 2.5mg/kg ip, were both similarly effective, reversing 14 
hypersensitivity completely at peak effect and remaining statistically significant for 180 15 
and 140min, respectively. The mean±SEM percentage reversals of hypersensitivity 16 
from 20-140min following administration were 94.4±6.9% (n=6) for lapatinib and 17 
75.5±9.0% (n=4) for afatinib, respectively (Fig. 3B). Animals treated with inhibitors of 18 
ErbB1, ErbB2 or combinations of these were closely observed and showed no 19 
apparent changes in locomotor activity, motor co-ordination or any evidence of 20 
sedation. 21 
 22 
Evidence for ErbB1:ErbB2 interaction in CCI-induced hypersensitivity  23 
 In order to evaluate any direct interaction between ErbB1 and ErbB2 in small 24 
DRG cells, we used a Proximity Ligation Assay, which relies on hybridisation between 25 
DNA-tagged secondary antibodies to produce an amplified fluorescent signal if the 26 
epitopes recognised by two, species-distinct, primary antibodies are in close proximity 27 
(Fredriksson, Gullberg et al. 2002). Figure 3C shows that ErbB1:ErbB2 proximity 28 
ligation in peripherin-positive DRG cells from naïve animals yielded a low fluorescent 29 
signal, which was strongly and significantly increased following CCI. Control 30 
experiments using rabbit ErbB1 and mouse ErbB3 or ErbB4 antibodies showed 31 
minimal proximity ligation signals from DRG cells of naïve or CCI rats. These findings 32 
provide explicit evidence for close interaction of ErbB1 and ErbB2 in nociceptive C-33 
fibres following nerve injury.  34 
In the classical paradigm of ErbB receptor activation, ligand binding induces 35 
receptor dimerisation, which leads to activation of the intrinsic tyrosine kinase function 36 
of the monomers and autophosphorylation or transphosphorylation of intracellular 37 
tyrosine residues (Weiss and Schlessinger 1998). ErbB2 lacks any known direct 38 
ligand, but readily heterodimerises with each of the other ErbB monomers (Graus-39 
Porta, Beerli et al. 1997, Tzahar, Pinkas-Kramarski et al. 1997), so may act as a 40 
subservient, signalling co-receptor in ErbB1:ErbB2 heterodimers. ErbB2 shows 41 
prominent auto-/trans-phosphorylation at Tyr1221/1222 upon activation (Ricci, 42 
Lanfrancone et al. 1995). Using a phospho-specific antibody that specifically 43 
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recognises ErbB2 phosphorylated at Tyr1221/1222, we showed a marked increase in 1 
staining in small, ErbB1-positive DRG cells following CCI, which was reversed by 2 
erlotinib treatment (at a dose of 10mg/kg ip, 1hr) (Fig. 3D). This indicates that ErbB2 3 
auto-/trans-phosphorylation occurs through an ErbB1-dependent mechanism 4 
following nerve injury; most likely representing the function of ErbB1:ErbB2 5 
heterodimers. 6 
 Given the accumulating evidence for ErbB1:ErbB2 co-engagement following 7 
nerve injury, we investigated whether ErbB1 and ErbB2 blockers might interact 8 
functionally in producing analgesia. We selected very low doses of erlotinib 9 
(0.33mg/kg) and mubritinib (1mg/kg) that produced just discernible analgesia, (only 10 
9.9±3.1% and 11.4±3.7% reversal of mechanical hypersensitivity when averaged over 11 
20-140min, n=4 in each case). Administration of these in combination produced clearly 12 
greater than additive analgesia (52.9±11.1% reversal of hypersensitivity, p<0.01, n=4, 13 
with complete reversal at peak effect and statistically significant effects for up to 14 
100min, Fig. 3E). Formal assessment of synergy using Bliss Additivism effect-based 15 
modelling (Berenbaum 1981, Borisy, Elliott et al. 2003), for combinations of erlotinib 16 
through the range 0.1-3.3mg/kg with mubritinib 1.0mg/kg, showed consistently greater 17 
observed responses than those predicted from combining individual effects, with more 18 
than 3.8-fold reduction in EC50 for observed compared to predicted combination dose-19 
response curves (p<0.001 by Extra Sum of Squares F-test; Fig. 3F). Two further, 20 
structurally distinct selective ErbB1 and ErbB2 inhibitors, were administered 21 
separately at low dose and then in combination, to independently confirm the concept 22 
of synergistic analgesic effects from dual ErbB1/ErbB2-targeting. Falnidamol 23 
(0.33mg/kg) and tucatinib (1.0mg/kg) individually produced 9.0±1.6% and 13.8±3.8% 24 
reversal of mechanical hypersensitivity, whereas in combination they produced 25 
54.9±6.1% reversal over 20-140min following administration, clearly much greater 26 
than the 21.6±4.1% predicted from Bliss Additivism modelling (p<0.01 by unpaired t-27 
test, n=4, Fig. 3G). These observations fully support the idea that ErbB1 and ErbB2 in 28 
C-fibre nociceptors co-operate in leading to nerve injury-induced hypersensitivity and 29 
suggest that conjoint administration of agents to block both ErbB1 and ErbB2 may 30 
represent a favourable strategy for analgesia.  31 
 32 
Evidence that peripheral terminals of nociceptors can be sensitised by an 33 
ErbB1-dependent process following CCI. 34 
In naïve rats, intradermal injection of EGF or heparin-binding EGF (another 35 
ErbB1-selective ligand) was reported to have no effect, whereas GDNF or NGF 36 
caused lasting hypersensitivity in a paw pressure withdrawal test (Andres, Meyer et 37 
al. 2010, Ferrari, Bogen et al. 2010). Nonetheless, as we had found ErbB1 abundantly 38 
expressed in the cell bodies of small, nociceptive DRG cells, some deployment to 39 
peripheral nerve terminals would be anticipated. To investigate whether peripherally 40 
localised ErbB1 might play a role in nerve injury-induced sensitisation of nociceptors, 41 
we carried out intraplantar injections in both naïve and CCI rats and assessed 42 
mechanical hypersensitivity by measuring von Frey PWT scores. Table 3 shows that 43 
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intraplantar injection of EGF amplified the ipsilateral hypersensitivity in CCI animals 1 
but not in naïve controls. No changes were seen in contralateral PWT values and 2 
contralateral injection of EGF had no effect on either contralateral or ipsilateral PWT 3 
values. These findings suggest that the effect observed upon ipsilateral injection was 4 
a local, not systemically mediated, action and that some event brought about by nerve 5 
injury (perhaps local neuroinflammatory processes) was required to prime the 6 
nociceptors before an active role of ErbB1 was revealed. The effect of EGF was not 7 
mimicked by neuregulin1-b1 EGF domain (NRG1; a selective ErbB3/ErbB4 ligand, 8 
matching our evidence for minimal expression of these proteins in small nociceptive 9 
DRG cells. The EGF-evoked amplification of hypersensitivity was however prevented 10 
by intraplantar co-injection of erlotinib, confirming the anticipated targeting of ErbB1, 11 
and also by mubritinib, consistent with our other evidence for ErbB1 acting by way of 12 
ErbB1:ErbB2 heterodimers. Pilot experiments in CIPN mice showed similar marked 13 
amplification of hypersensitivity lasting from 20-80min following intraplantar injection 14 
of EGF (80ng), but no discernible effect in naïve controls.  15 
 16 
Evidence for ErbB1 transactivation by intracellular signalling from other 17 
receptors following CCI 18 
ErbB1 can act as a hub for transactivation by signals from diverse G protein-19 
coupled receptors (GPCRs), chemokine-, and orphan-receptors (Wang 2016, Kose 20 
2017). Gq-, Gi- and Gs-linked GPCRs can lead to ErbB1 transactivation by a 21 
mechanism involving Src and the recruitment of signalling adapter molecules including 22 
Grb2 and Gab1 (Daub, Wallasch et al. 1997, Maudsley, Pierce et al. 2000, Drube, 23 
Stirnweiss et al. 2006, Qian, Peng et al. 2016). While activation of Gi-linked GPCRs, 24 
such as for lysophosphatidic acid, is reported to lead to Src-dependent tyrosine 25 
phosphorylation of ErbB1, ErbB2 phosphorylation was not directly increased (Luttrell, 26 
Della Rocca et al. 1997). This is consistent with the idea of Src-dependent targeting 27 
of ErbB1, rather than ErbB2, representing the primary step in the transactivation of 28 
ErbB1:ErbB2 heterodimers by diverse upstream regulators. Src phosphorylation of 29 
ErbB1 specifically at Tyr845 leads to activation of ErbB1 signalling (Tice, Biscardi et 30 
al. 1999, Baumdick, Gelleri et al. 2018). Similarly, another Src family kinase, Yes, 31 
phosphorylates ErbB1 at sites including Tyr845 (but not Tyr1068), causing activation 32 
of downstream signalling, while the receptor is located intracellularly in endosomes 33 
(Su, Bryant et al. 2010). Multiple candidate activators; inflammatory mediators, 34 
chemokines and cytokines are released during the local neuroinflammation following 35 
nerve injury (White, Sun et al. 2005, Uceyler, Tscharke et al. 2007, Sacerdote, Franchi 36 
et al. 2008, Ji, Xu et al. 2014, Zhu, Cao et al. 2014). GPCRs for peptides (such as 37 
bradykinin), lipids (such as prostaglandins), proteases (such as thrombin) and 38 
chemokines (such as CCL2), as well as receptors for cytokines, such as interleukin-39 
1b and TNF-a, can all activate Src-family kinases (Viviani, Bartesaghi et al. 2003, van 40 
Vliet, Bukczynska et al. 2005, Davis, Tabarean et al. 2006, Hardyman, Wilkinson et 41 
al. 2013, Ghosh, Green et al. 2016, Kose 2017, Zhang, Han et al. 2017, Yao, Fang et 42 
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al. 2019); a signalling event reported to occur in primary afferents during neuropathic 1 
pain (Chen, Walwyn et al. 2014, Lam, Momeni et al. 2018).  2 
To explore whether Src-dependent transactivation of ErbB1 was important in 3 
nerve injury-induced hypersensitivity, we firstly assessed the effect of selective 4 
inhibitors of Src on CCI-induced hypersensitivity in paw withdrawal thresholds from 5 
von Frey filaments. The potent Src inhibitor, dasatinib (O'Hare, Walters et al. 2005), 6 
at a dose of 3mg/kg ip, and the Src family-specific kinase inhibitor, A419259 (Wilson, 7 
Schreiner et al. 2002), at a dose of 15mg/kg ip, both caused clear reversal of CCI-8 
induced hypersensitivity, with complete reversal of hypersensitivity at peak and 9 
statistically significant reversal for 60min and 50min in each case (Fig. 4A). The 10 
amplification of mechanical hypersensitivity caused by intraplantar injection of 100ng 11 
EGF ipsilateral to CCI (48.1±14.0% reduction in PWT, Table 3) was also prevented by 12 
local co-administration of 0.73ng dasatinib (2.8±13.4% reduction in PWT, n=4). These 13 
observations strongly support the idea of a key role for Src throughout primary 14 
nociceptive neurons in bringing about neuropathic hypersensitivity (and are consistent 15 
with previous reports). In future studies, outwith the scope of current work, it would be 16 
of interest to assess the possibility of synergistic analgesic effects arising from 17 
combined delivery of Src- and ErbB1 inhibitors.  18 
 As Src activity is normally restrained due to constitutive phosphorylation at 19 
Tyr527 by Csk and disinhibited by intracellular signals leading to dephosphorylation at 20 
this locus (Hunter 1987), we investigated the status of phosphorylation at this site, 21 
using an antibody specific for phospho-Src (Tyr527). We showed significantly 22 
decreased staining in small, ErbB1-positive DRG cells following CCI, which would be 23 
predicted to reflect increased Src activity (Fig. 4B). This was unaffected by erlotinib, 24 
exactly as would be expected for a signalling process upstream of ErbB1, that could 25 
drive its transactivation or priming sensitisation by neuroinflammatory signals. 26 
 We further investigated phosphorylation of ErbB1 at the Src-target site, Tyr845. 27 
Fig. 4C shows that CCI induced a marked increase in staining with a phospho-ErbB1 28 
(Tyr845)-specific antibody in small, peripherin-positive DRG cells. This was blocked, 29 
as expected, by dasatinib treatment, but was unaltered by erlotinib, consistent with 30 
this step representing an upstream regulation of ErbB1 that is independent of ErbB1’s 31 
own catalytic activity.  32 
 33 
Downstream signalling by ErbB1 activated following CCI 34 
Following ErbB1 activation, Tyr1068 is amongst the most prominent receptor 35 
autophosphorylation/transphosphorylation sites, which forms the major recruitment 36 
site for the adapter proteins, Grb2 and Gab1; leading to signalling through ERK MAP 37 
kinase and PI 3-kinase/Akt (Rojas, Yao et al. 1996, Olayioye, Neve et al. 2000, 38 
Rodrigues, Falasca et al. 2000, Nishida and Hirano 2003, Mattoon, Lamothe et al. 39 
2004). Figure 5A shows that ErbB1 phosphorylation at Tyr1068 was clearly increased 40 
following CCI and this was reversed by treatment with erlotinib (10mg/kg, for 1hr), 41 
suggesting that Tyr1068 phosphorylation was maintained by an active, rapidly turning-42 
over process following nerve injury. The potent Src inhibitor, dasatinib (3mg/kg) was 43 
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similarly effective, consistent with an upstream role of Src in bringing about ErbB1 1 
autophosphorylation (Fig. 5A). Figure 5B displays the subcellular distribution of 2 
phospho-ErbB1 (Tyr1068) immunoreactivity in DRG neurons from naïve, CCI and 3 
erlotinib-treated CCI animals. Both high power images of individual cells and 4 
fluorescence intensity profiles of transects from the nuclear perimeter to the plasma 5 
membrane at the cell apex, show that phospho-ErbB1 (Tyr1068) was clearly increased 6 
following CCI and this increment was reversed by erlotinib treatment; n=8 in each 7 
case. The increase in ErbB1 phosphorylation at Tyr1068 following nerve injury was 8 
however, predominantly at an intracellular (perinuclear) site, as opposed to plasma 9 
membrane; consistent with its induction by an intracellular signalling process rather 10 
than an external ligand. The close molecular engagement of Gab1 with ErbB1 was 11 
explicitly demonstrated by Proximity Ligation Assay, which shows ErbB1:Gab1 12 
proximal interaction was significantly increased in peripherin-positive DRG cells 13 
following CCI and that this increment was reversed by in vivo treatment with erlotinib 14 
or mubritinib (Fig. 5C), consistent with roles of the tyrosine kinase function of both 15 
ErbB1 and ErbB2 in Gab1 recruitment. The subcellular distribution of Gab1 16 
immunoreactivity itself was not studied in detail. Trials for antibody specificity were 17 
only carried out with naïve tissue and examined at low power, where staining appeared 18 
to be distributed throughout the cytoplasm. Whether this distribution might be altered 19 
in CCI tissue was not assessed. 20 
Two downstream signalling cascades are activated following ErbB1 21 
phosphorylation at Tyr1068; the PI 3-kinase/Akt and ERK MAP kinase pathways 22 
(Olayioye, Neve et al. 2000). Akt is activated as a consequence of PIP3 generation by 23 
PI 3-kinase, which may occur as a result of its Gab1-dependent recruitment to 24 
phospho-ErbB1 (Tyr1068). The activation state of Akt can be monitored by its 25 
obligatory phosphorylation at Ser473 (Sarbassov, Guertin et al. 2005). Figure 6A 26 
shows that phospho-Akt (Ser473) staining in small, ErbB1-positive DRG cells was 27 
significantly increased following CCI and that this increment was fully reversed by 28 
erlotinib (10mg/kg ip, 1hr), the highly selective Akt inhibitor, ipatasertib (GDC-0068) 29 
(Lin, Sampath et al. 2013) (20mg/kg ip, 1hr) or the Src inhibitor, dasatinib (3mg/kg ip, 30 
1 hr). Figure 6B shows that two selective Akt inhibitors of distinct structure, ipatasertib 31 
and afuresertib, both reversed CCI-induced mechanical hypersensitivity in the von 32 
Frey paw withdrawal test, at doses providing effective target coverage in vivo 33 
(20mg/kg ip and 3.3mg/kg ip, respectively) (Lin, Sampath et al. 2013, Dumble, 34 
Crouthamel et al. 2014). Both agents caused significant reversal (p<0.01) of 35 
hypersensitivity for at least 160min following administration, with mean±SEM 36 
percentage reversal of hypersensitivity from 20-140min of 87.6±6.8%, n=6 and 37 
75.5±8.5%, n=5, respectively. These observations indicate that Akt is activated in 38 
ErbB1-expressing small DRG cells following CCI and that this is prevented by erlotinib 39 
blockade of ErbB1 signalling or dasatinib inhibition of the upstream ErbB1 regulator, 40 
Src. Highly selective Akt inhibitors also cause marked and sustained reversal of CCI-41 
induced mechanical hypersensitivity. These findings suggest that activation of Akt by 42 
ErbB1 plays a key role in hypersensitivity following nerve injury. It is notable that the 43 
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functional lifetime of ErbB1 and its co-immunoprecipitation with Gab1 and the p85 1 
subunit of PI 3-kinase are reported to be increased by the co-expression of ErbB2 2 
(Hartman, Zhao et al. 2013). Whether co-administration of ErbB1/ErbB2 inhibitors with 3 
blockers of Akt might lead to further synergistic enhancement of analgesia would be 4 
interesting to explore in follow-on studies.  5 
ERK MAP kinase is also activated upon ErbB1 autophosphorylation at Tyr1068, 6 
through recruitment of the adapter Grb2, or potentially indirectly through a Gab1/SHP-7 
2 complex (Nishida and Hirano 2003), to trigger a kinase cascade leading to MEK and 8 
ERK. Activation of ERK was monitored by its obligatory phosphorylation by MEK at 9 
Thr202 and Tyr204 (Robinson and Cobb 1997). While the majority of DRG cells 10 
positive for phospho-ERK (Thr202/Tyr204) were also ErbB1-positive, a sizeable 11 
fraction of this ERK phosphorylation occurred in cells that did not stain for ErbB1 12 
(25.2±5.3%, n=4), and this proportion was unaltered following CCI, or CCI plus 13 
erlotinib treatment. Correspondingly, highly selective blockers of ERK MAP kinase, 14 
(ravoxertinib, GDC-0994) (Blake, Burkard et al. 2016) or its upstream regulator, MEK, 15 
(AZD-8330) (Wallace, Lyssikatos et al. 2005), produced only modest reversal of CCI-16 
induced mechanical hypersensitivity. The mean±SEM values for percentage reversal 17 
of CCI-induced hypersensitivity in the von Frey test were 9.7±2.6% (n=4) and 18 
35.8±4.6% (n=11), over 20-140min following administration, for 30mg/kg ravoxertinib 19 
and for 1.25mg/kg AZD-8330 (doses that have been documented to provide effective 20 
target coverage in vivo). In comparison with the Akt inhibitor results, these 21 
observations suggest a relatively minor involvement of ERK in driving the 22 
hypersensitivity measured here. This corresponds to reports of rather transient ERK 23 
activation in DRG and dorsal horn neurons, following nerve injury (Obata, Yamanaka 24 
et al. 2004, Zhuang, Gerner et al. 2005, Ji, Gereau et al. 2009). While EGF treatment 25 
of cultured DRG neurons does cause activating phosphorylation of Shc (an 26 
intermediary adapter) for the ERK MAP kinase pathway (Ganju, O'Bryan et al. 1998), 27 
ERK itself is reported to be only minimally activated (Andres, Meyer et al. 2010).  28 
 29 
ErbB1-dependent activation of Akt targets downstream vesicular trafficking 30 
Among the range of Akt substrates discovered in an unbiased search using an 31 
antibody raised against the consensus Akt phosphorylation motif (Kane, Sano et al. 32 
2002) was AS160 (TBC1D4). AS160 is now known to act as a Rab-GAP and 33 
participate (upon its phosphorylation and inhibition by Akt at Thr642) in insulin-induced 34 
translocation of GLUT4 storage vesicles in adipocytes (Sano, Kane et al. 2003). We 35 
hypothesised that following nerve injury, ErbB1 activation of Akt might similarly 36 
regulate trafficking of targets relevant to neuronal excitability in sensory neurons. 37 
Figure 7A shows that the percentage of ErbB1-positive DRG cells staining for 38 
phospho-AS160 (Thr642) was markedly increased following CCI and that this 39 
increment was reversed by treatment for 1hr with either erlotinib (10mg/kg ip) or 40 
ipatasertib (20mg/kg ip), n=4 in each case; fully consistent with our hypothesis. Levels 41 
of pan-AS160 staining in ErbB1-positive DRG cells were unaltered following CCI 42 
(69.7±3.6% in naïve, and 71.6±2.4% in CCI, n=4 in each case). Even in low power 43 
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images of phospho-AS160 (Thr642) staining, it was obvious that the marked CCI-1 
induced increase was intracellularly localised in a prominent perinuclear ring of 2 
fluorescence. High power images and transect fluorescence intensity analysis of 3 
phospho-AS160 (Thr642) staining in individual ErbB1-positive DRG cells confirmed 4 
this, with a marked (3-fold) increase in maximal intensity following CCI that occurred 5 
entirely within 2µm of the nuclear perimeter (Fig. 7B, n=8 in each case). The CCI-6 
induced increment was reversed by erlotinib, mubritinib (15mg/kg ip, 1 hr) or 7 
ipatasertib treatment, confirming the involvement of ErbB1, ErbB2 and Akt in this 8 
response. AS160 and its Akt-phosphorylated form have been identified at both 9 
intracellular and plasma membrane locations in various cell types (Larance, Ramm et 10 
al. 2005, Ng, Ramm et al. 2010, Zheng and Cartee 2016), although here, in 11 
nociceptive afferent neurons, as in muscle for example (Zheng and Cartee 2016), the 12 
location is almost entirely intracellular.  13 
AS160 has been shown to interact directly with LRP1, a chaperone/cargo 14 
protein in GLUT4 storage vesicles, that is essential for GLUT4 trafficking to the plasma 15 
membrane (Jedrychowski, Gartner et al. 2010, Brewer, Habtemichael et al. 2014). 16 
Interestingly, LRP1 has been identified as a key factor in the trafficking of multiple 17 
cargoes to the plasma membrane, including b1 integrin and voltage-sensitive ion 18 
channels (Salicioni, Gaultier et al. 2004, Lillis, Van Duyn et al. 2008, Parkyn, 19 
Vermeulen et al. 2008, Kadurin, Rothwell et al. 2017, Au, Ying et al. 2018). As such a 20 
role could potentially play a part in increased nociceptor excitability following nerve 21 
injury, we investigated the subcellular distribution of LRP1 immunoreactivity in DRG 22 
cells after CCI. Figure 7C shows example high power images and transect 23 
fluorescence intensity analysis of LRP1 staining in individual ErbB1-positive DRG 24 
cells. LRP1-immunoreactivity was found in small clusters, consistent with a vesicular 25 
localisation, which in naïve animals was limited to the inner, perinuclear half of the 26 
transect range. In CCI animals, a significant increase in LRP1 staining (with greater 27 
clustering) was observed in the outer portion of the transect range and this increment 28 
was reversed by treatment with erlotinib or ipatasertib, again defining ErbB1 and Akt 29 
involvement in the response (n=9 in each case).   30 
 31 
CCI-induced ion channel trafficking in nociceptors through ErbB1 activation of 32 
Akt 33 
Numerous ion channels could contribute to altered excitability and action 34 
potential generation in nociceptors if they show increased localisation at the plasma 35 
membrane following injury. The voltage-sensitive Na+ channels, Nav1.7/1.8/1.9, are 36 
selectively expressed in nociceptors and are thought to play key roles in threshold 37 
setting, and in the generation and repetitive firing of action potentials (Dib-Hajj, Black 38 
et al. 2015, Dib-Hajj, Geha et al. 2017, Hoffmann, Kistner et al. 2017). Molecular 39 
genetics of human hereditary channelopathies with altered pain sensation has directly 40 
implicated each of these channels in pain processing, including hypersensitive 41 
neuropathic pain states (Dib-Hajj, Geha et al. 2017, Huang, Vanoye et al. 2017). They 42 
each show a predominantly intracellular location under basal conditions, suggesting 43 
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that their trafficking to the plasma membrane could well lead to increased excitability 1 
(Amaya, Decosterd et al. 2000, Okuse, Malik-Hall et al. 2002, Bao 2015). Analysis of 2 
Nav1.7/1.8/1.9 expression using specific antibodies showed very high proportions of 3 
expression in ErbB1-positive small DRG cells (97.1±5.8%, 71.6±6.3% and 90.3±6.6%, 4 
respectively, n=4 in each case). While CCI caused no discernible change in Nav1.7 or 5 
Nav1.8 expression levels, Nav1.9 expression and subcellular deployment were 6 
significantly altered. We observed a slight reduction in the number of ErbB1-positive 7 
DRG cells co-expressing Nav1.9 to 75.3±7.9% of ErbB1-positive cells (p<0.05, t-test), 8 
but a marked redeployment of the channel towards the plasma membrane (Fig. 8A). 9 
A partial reduction in expression of Nav1.9 following sciatic, but not trigeminal nerve 10 
injury has been reported previously (Dib-Hajj, Fjell et al. 1999, Luiz, Kopach et al. 11 
2015), while expression is increased in a bone cancer model, which likely incorporates 12 
a nerve injury component (Qiu, Jiang et al. 2012). Nerve injury-induced trafficking of 13 
Nav1.9, which has a long-lasting impact on nociceptor firing threshold (Hoffmann, 14 
Kistner et al. 2017), has not previously been reported. Figure 8A shows high power 15 
images of individual ErbB1-positive DRG cells and transect fluorescence intensity 16 
analysis indicating marked recruitment of Nav1.9 to sites adjacent to the apical plasma 17 
membrane (transect bins 43-49 out of 50) following CCI and its efficient reversal by 18 
treatment with erlotinib or ipatasertib (n=8 in each case). It was not possible to readily 19 
assess whether Nav1.9 blockade would reverse CCI-induced pain hypersensitivity in 20 
the current experiments, as no highly selective small molecule Nav1.9 inhibitors are 21 
available (Dib-Hajj, Black et al. 2015, Lin, Santos et al. 2016). Similar (but less marked) 22 
results were observed with Nav1.8, indicating significant CCI-induced recruitment to 23 
transect bins 46-50 and reversal by erlotinib treatment (n=9 in each case), while no 24 
significant changes were detected in Nav1.7 distribution (Supplementary Figure). 25 
Figure 8B shows that Proximity Ligation Assay using specific Nav1.9 and LRP1 26 
antibodies, identified a close molecular interaction of these two proteins in peripherin-27 
positive DRG cells, which was significantly increased following CCI, and reversed by 28 
treatment with erlotinib. This fully supports the idea of LRP1 driving Nav1.9 29 
translocation to the plasma membrane following CCI, through an ErbB1, Akt and 30 
AS160-dependent process. 31 
Several voltage-sensitive Ca2+ channel types are also expressed in DRG 32 
neurons, particularly L-type, generally involving Cav1.2 or Cav1.3 a1-subunits, and 33 
also N-type, involving Cav2.2, which between them contribute the majority of voltage-34 
dependent Ca2+ current (Heinke, Balzer et al. 2004, Woodall, Richards et al. 2008, 35 
Bourinet, Altier et al. 2014). Cav1.2 and Cav2.2 have both been shown to undergo PI 36 
3-kinase/Akt-dependent trafficking to the plasma membrane of transfected fibroblasts 37 
and DRG neurons (Viard, Butcher et al. 2004), so could potentially play a part in the 38 
ErbB1-dependent hypersensitivity identified following nerve injury. We focused here 39 
on Cav1.2, as intrathecal administration of L-type Ca2+ channel blockers (affecting 40 
DRG as well as spinal cord (Cao, Qian et al. 2016)) produces analgesia in chronic 41 
pain states (Vanegas and Schaible 2000, Yaksh 2006), while knockdown of Cav1.2 42 
specifically reverses neuropathy-associated mechanical hypersensitivity (Fossat, 43 
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Dobremez et al. 2010). In contrast, Cav1.3 knockout mice lack any pain phenotype 1 
(Clark, Nagano et al. 2003). Cav1.2 is also of particular interest in relation to nociceptor 2 
excitability due to its subcellular localisation, not only at the plasma membrane and 3 
intracellularly, but also in the Axon Initial Segment (AIS), where it may play a role in 4 
excitability setting (Brandao, Dell'Acqua et al. 2012). A large proportion of Cav1.2-5 
positive cells were also ErbB1-positive, and this was unaltered following nerve injury 6 
(74.1±3.7% naïve, and 66.5±3.9% CCI, n=4 in each case). The subcellular distribution 7 
of Cav1.2 however, was strikingly altered following nerve injury. Figure 8C shows high 8 
power images of individual cells and fluorescence intensity analysis of cell transects. 9 
This indicates remarkable trafficking of Cav1.2 to the apical plasma membrane and 10 
proximal stem axon following CCI, which was reversed by treatment with erlotinib or 11 
ipatasertib (n=8 in each case). Nerve injury-induced translocation of Cav1.2 to such 12 
sites in nociceptors could contribute importantly to increased excitability. The reversal 13 
of this response by erlotinib and ipatasertib indicates its dependence on the ErbB1/Akt 14 
pathway we have elucidated above.  15 
 16 
Discussion  17 
 18 
Our results provide powerful evidence that highly selective small molecule 19 
inhibitors of the tyrosine kinase function of ErbB1 (TKIs) reverse hypersensitivity in 20 
rodent neuropathic pain models. This represents robust corroboration of previous 21 
clinical findings with both ErbB1 antibody reagents, such as cetuximab or 22 
panitumumab, and small molecule ErbB1-selective TKIs, such as erlotinib and gefitinib 23 
(Kersten and Cameron 2012, Kersten, Cameron et al. 2013, Kersten, Cameron et al. 24 
2015). It was not possible to test cetuximab or panitumumab here due to their 25 
humanised/human immune origins. Our results using the CCI model of neuropathic 26 
mechanical pain hypersensitivity in rats (von Frey paw withdrawal threshold) gave a 27 
mean IC50 value of 1.4mg/kg ip for erlotinib, similar estimated potencies for gefitinib 28 
and AG 1478, and robust analgesic effects of several structurally distinct ErbB1-29 
selective TKIs (Table 2). These observations were reproduced in the mouse CIPN 30 
model, which showed mean IC50 values of 3.2, 2.4 and 3.0mg/kg ip for erlotinib, 31 
gefitinib and AG 1478, respectively. The effective analgesic doses here are in the 32 
range of approved human dosing. Similar analgesic effects of small molecule ErbB1-33 
selective TKIs have been reported using various inflammatory and neuropathic pain 34 
models in mice and the CCD, chronic DRG compression, model in rats (Martin, Smith 35 
et al. 2017, Wang, Liu et al. 2019). In many cases though, the mean IC50 values 36 
reported were notably higher, both in inflammatory pain models (formalin phase-2 and 37 
Complete Freund’s Adjuvant), and particularly in neuropathic pain models (Spared 38 
Nerve Injury and CCI), where IC50s for gefitinib and AG 1478 ranged from 77 to around 39 
300mg/kg (Martin, Smith et al. 2017). The basis for this disparity is unclear, although 40 
the analgesic signal is fully corroborated.   41 
The present study provides substantive evidence for the highly selective 42 
expression of ErbB1 in small unmyelinated nociceptors. In the CCI model here, ErbB1 43 
expression is unaltered following nerve injury, in contrast to findings from the CCD 44 
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(DRG compression) model (Wang, Liu et al. 2019). We found a high degree of co-1 
localisation of ErbB1 with ErbB2, but not ErbB3 or ErbB4, in small unmyelinated 2 
nociceptors. Our study further delivers fundamental new insights by showing that 3 
ErbB1 is likely to act as a heterodimer with ErbB2 in driving neuropathic pain 4 
hypersensitivity. The key evidence arises from converging experimental approaches;  5 
proximity ligation showing direct ErbB1:ErbB2 interaction in DRG, analgesia induced 6 
by either ErbB1 and ErbB2 inhibitors (both systemically and peripherally), crossed 7 
blockade of an activation marker by inhibiting the partner receptor, and importantly, 8 
definitive synergism in the analgesia produced by co-administration of ErbB1 and 9 
ErbB2 inhibitors. This synergistic co-operation of ErbB1 and ErbB2 inhibitors in 10 
delivering analgesic efficacy against neuropathic pain identifies clear translational 11 
potential; highlighting a strategy for enhanced pain relief with lesser side effects than 12 
might be achieved by an EGFR inhibitor alone.  13 
Our evidence that Src could well play a key role in triggering pro-excitatory 14 
ErbB1 processes in nociceptive afferents is consistent with reports of Src activation in 15 
DRG (including in TRPV1-positive afferents) in both neuropathic and inflammatory 16 
pain models (Alessandri-Haber, Dina et al. 2004, Jin, Morsy et al. 2004, Zhang, Huang 17 
et al. 2005, Liu, Liu et al. 2015). Src is readily activated in DRG by cytokines (IL-1b 18 
and CXCL12) (Igwe 2003, Rivat, Sebaihi et al. 2014), which would support the 19 
hypothesis that ErbB1 activation in CCI here may result from intracellular 20 
transactivation, potentially as a result of nerve injury-induced neuroinflammation. Src 21 
phosphorylation of ErbB1 at Tyr845 leads to facilitated or direct activation of ErbB1 22 
signalling (Tice, Biscardi et al. 1999, Baumdick, Gelleri et al. 2018), thereby obviating 23 
the need for increased availability of an extracellular EGF-like ligand. Nevertheless, 24 
genetic association of a SNP in the gene locus for epiregulin (an ErbB1 and ErbB4 25 
receptor ligand) in patient cohorts with chronic temporomandibular disorder (TMD) 26 
pain has been identified (Martin, Smith et al. 2017), although acute pain seems to be 27 
inversely correlated (Verma, Khoury et al. 2020).  Both inflammatory and neuropathic 28 
pain models in mice result in increased blood levels of epiregulin and its intrathecal 29 
administration produces modest hypersensitivity in baseline thermal and mechanical 30 
responses as well as a dose-dependent increase in licking/biting behaviour in the 31 
second phase of the formalin test (Martin, Smith et al. 2017). However, the facilitation 32 
of formalin responses was not replicated by any of 4 other ErbB1 agonist-ligands, 33 
despite the binding affinity of epiregulin to ErbB family receptors (including ErbB1 34 
homodimers and ErbB1:ErbB2 heterodimers) being lower than that of all other EGF 35 
family ligands (Toyoda, Komurasaki et al. 1995, Shelly, Pinkas-Kramarski et al. 1998, 36 
Jones, Akita et al. 1999, Sato, Nakamura et al. 2003, Freed, Bessman et al. 2017). 37 
The application of epiregulin to dorsal nerve roots in rats showed disparate effects on 38 
the spontaneous or C-fibre-evoked activity of dorsal horn neurons (Kongstorp, 39 
Schjolberg et al. 2019), matching the dichotomous molecular genetics findings (Martin, 40 
Smith et al. 2017, Verma, Khoury et al. 2020). Similarly, while systemic infusion of an 41 
epiregulin-neutralising antibody speeded the recovery from hypersensitivity in a nerve 42 
injury model, this had mixed effects in an inflammatory model and exacerbated 43 
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capsaicin-evoked pain responses (Verma, Khoury et al. 2020). With respect to the 1 
specific role of ErbB1, although attenuation of epiregulin facilitation of phase-2 2 
formalin responses by the ErbB1-selective TKI, AG 1478, was reported (Martin, Smith 3 
et al. 2017), the fact that this itself reduces formalin responses, complicates 4 
interpretation. Similarly, although epiregulin facilitation of formalin responses was 5 
absent in (heterozygous) mutant mice with a large deletion of the ErbB1 extracellular 6 
domain, the mutants showed significantly altered basal formalin responses. Overall, 7 
while systemic epiregulin levels increase in chronic pain models and may indeed 8 
contribute to hypersensitivity, there is limited explicit evidence that this relates 9 
specifically to ErbB1 in primary nociceptive afferents.  10 
To explore the role of ErbB1 in the peripheral terminals of nociceptors, we 11 
carried out intraplantar injections of EGF and assessed mechanical paw withdrawal 12 
thresholds (Table 3).  EGF showed no discernible effect in naïve animals, in 13 
agreement with previous observations (Andres, Meyer et al. 2010, Ferrari, Bogen et 14 
al. 2010, Araldi, Ferrari et al. 2018), but a clear amplification of ipsilateral 15 
hypersensitivity after nerve injury. This suggests that ErbB1 plays a role in nociceptive 16 
processing only in chronic injury-induced hypersensitive states. The EGF response 17 
was specific to the injured limb, reversed by local erlotinib, mubritinib or dasatinib 18 
(indicating ErbB1, ErbB2 and Src involvement) and was not mimicked by neuregulin-19 
1-b1 EGF domain (indicating lack of ErbB3/4 involvement). Interestingly, the 20 
prolongation of intradermal PGE2-induced mechanical hypersensitivity caused by 21 
repeated administration of µ-opioid receptor agonist, is reported to be attenuated by 22 
inhibitors of both ErbB1 and Src (Araldi, Ferrari et al. 2018), emphasising a key role of 23 
ErbB1 in GPCR-induced pain hypersensitivity. In that model, intradermal EGF did not 24 
on its own affect pain responses, as described here. Responses to PGE2 were 25 
unaltered 5 days after EGF administration, which would align with our observations 26 
that concurrent nerve injury is required to reveal a sensitising effect of ErbB1 activation 27 
and support the hypothesis that intracellular signalling plays a key role in this 28 
connection. 29 
A number of reports have described the activation of Akt in DRG neurons in 30 
chronic pain hypersensitivity induced by nerve injury (Xu, Tu et al. 2007, Shi, Huang 31 
et al. 2009), chemotherapeutic-evoked neuropathy (Jiang, Zhang et al. 2016, Li, Chen 32 
et al. 2016), inflammation (Liang, Tao et al. 2013), bone cancer (Guan, Fu et al. 2015) 33 
and intradermal injection of capsaicin, ephrin or formalin (Sun, Yan et al. 2007, Guan, 34 
Lu et al. 2010, Martin, Smith et al. 2017). In many cases, administration of PI 3-kinase 35 
or Akt inhibitors attenuated pain hypersensitivity, matching our observations here with 36 
the second generation highly selective Akt inhibitors, ipatasertib and afuresertib. 37 
Various reports have also outlined changes in mTOR and protein translational 38 
machinery (significant downstream targets of Akt) in neuropathic, inflammatory and 39 
formalin-induced pain models, with analgesic effects seen due to blockers of different 40 
elements (Xu, Zhao et al. 2010, Obara, Tochiki et al. 2011, Liang, Tao et al. 2013, 41 
Khoutorsky, Bonin et al. 2015, Martin, Smith et al. 2017). Epiregulin-induced 42 
enhancement of formalin-induced nocifensive behaviour was attenuated by inhibitors 43 
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of PI 3-kinase (but not MEK) and accompanied by increased Akt phosphorylation in 1 
DRG (Martin, Smith et al. 2017), potentially relating to ErbB1 activation. Epiregulin-2 
induced pain hypersensitivity was also diminished by inhibitors of mTOR and in mutant 3 
mice with disrupted elements of the protein translational machinery, indicating a clear 4 
functional role. In the current study we investigated whether alternative rapid Akt-5 
dependent processes such as ion channel trafficking may be key to the role of ErbB1 6 
in neuropathic pain and help explain the rapid analgesic effects of ErbB1 inhibitors.  7 
Akt has important cellular roles in the regulation of vesicular trafficking, for 8 
example in insulin-induced rapid translocation of the GLUT4 glucose transporter to the 9 
plasma membrane of adipocytes (Hill, Clark et al. 1999). The substrates for Akt 10 
phosphorylation include AS160 (TBC1D4), a Rab-GAP (GTPase-activating protein), 11 
which signals GLUT4 translocation by terminating vesicle retention upon its 12 
inactivating phosphorylation by Akt (Kane, Sano et al. 2002, Sano, Kane et al. 2003, 13 
Fujita, Hatakeyama et al. 2010). AS160 has a predominantly peri-nuclear subcellular 14 
localisation, associated with GLUT4 storage vesicles, from which it dissociates 15 
following insulin stimulation (Larance, Ramm et al. 2005). Akt-phosphorylated AS160 16 
(at Thr642) has been identified at both intracellular and plasma membrane sites after 17 
insulin stimulation of adipocytes (Ng, Ramm et al. 2010), although in muscle its 18 
localisation is entirely intracellular (Zheng and Cartee 2016), as we found here 19 
associated with ErbB1-dependant nociceptive hypersensitivity following nerve injury. 20 
An AS160 paralogue, TBC1D1, and AS250 (a Ral-GAP) may also contribute to Akt 21 
regulation of GLUT4 trafficking  (Sakamoto and Holman 2008, Peck, Chavez et al. 22 
2009, Chen, Leto et al. 2011, Leto and Saltiel 2012). We further showed that the 23 
AS160-interacting protein and vesicular chaperone/co-cargo, LRP1 (Jedrychowski, 24 
Gartner et al. 2010), which participates in the plasma membrane trafficking of various 25 
surface-deployed proteins, such as Cav2.2 (Kadurin, Rothwell et al. 2017), undergoes 26 
clustering and localisation closer to the plasma membrane following CCI. Crucially 27 
these changes were prevented by selective blockers of ErbB1 or Akt.   28 
In addition, we demonstrated increased ErbB1- and Akt-dependent trafficking 29 
of Nav1.9 and Nav1.8 (but not Nav1.7) to DRG somata plasma membrane following 30 
CCI (Fig. 8A, Supplementary Figure), a process that potentially could also occur in 31 
peripheral nociceptor endings. This matches human molecular genetics evidence 32 
associating these channels with hereditary painful neuropathies, and their disruption 33 
with insensitivity to pain (Dib-Hajj, Geha et al. 2017, Bennett, Clark et al. 2019). The 34 
electrophysiological characteristics of Nav1.8 point to a role in rapid re-priming and 35 
maintenance of repetitive firing (Dib-Hajj, Geha et al. 2017, Bennett, Clark et al. 2019). 36 
The activation of Nav1.9 by weak stimuli at hyperpolarised voltages and very delayed 37 
time-course of inactivation are consistent with a role in threshold setting of excitability 38 
(Dib-Hajj, Geha et al. 2017, Bennett, Clark et al. 2019). Many, but not all, knockdown, 39 
knockout and pharmacological studies indicate a role for Nav1.8 in both inflammatory 40 
and neuropathic pain (Porreca, Lai et al. 1999, Kerr, Souslova et al. 2001, Lai, Hunter 41 
et al. 2003, Nassar, Levato et al. 2005, Joshi, Mikusa et al. 2006, Dong, Goregoaker 42 
et al. 2007). Differences in findings may relate to the characteristics of particular 43 
mutant mouse lines and compensatory changes (Leo, D'Hooge et al. 2010). Although 44 
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no truly selective pharmacological selective agents are yet available  (Dib-Hajj, Black 1 
et al. 2015, Lin, Santos et al. 2016), knockout/deletion studies have implicated Nav1.9 2 
in inflammatory pain, but also in neuropathic and basal pain  (Porreca, Lai et al. 1999, 3 
Priest, Murphy et al. 2005, Amaya, Wang et al. 2006, Maingret, Coste et al. 2008, Leo, 4 
D'Hooge et al. 2010, Hockley, Boundouki et al. 2014, Osorio, Korogod et al. 2014, 5 
Lolignier, Bonnet et al. 2015, Luiz, Kopach et al. 2015, Hoffmann, Kistner et al. 2017). 6 
Very little is known however, of the processes involved in their deployment at the 7 
plasma membrane of DRG neurons. There is evidence that contactin and FHF1B 8 
interact directly with Nav1.9 and could play a role (Liu, Dib-Hajj et al. 2001, Liu, Dib-9 
Hajj et al. 2001), although FHF1B and contactin are also implicated in the 10 
function/trafficking of Nav1.5/1.3 (Liu, Dib-Hajj et al. 2003, Shah, Rush et al. 2004). 11 
The heterologous expression of functional Nav1.9 has proved difficult to achieve and 12 
is likely to require Navb subunits as well as probably additional, unknown factors 13 
(Goral, Leipold et al. 2015, Lin, Santos et al. 2016). Similarly, little is known of Nav1.8 14 
trafficking and its control, although interaction with annexin light chain p11 has been 15 
reported as a key factor (Okuse, Malik-Hall et al. 2002, Foulkes, Nassar et al. 2006). 16 
Annexin light chain p11 is also implicated in the plasma membrane trafficking of 17 
epithelial Na+ (ENaC) channels and related ASIC1a channels (Donier, Rugiero et al. 18 
2005, Cheung, Ismail et al. 2019), both of which can be driven by PI 3-kinase/Akt 19 
signalling (Markadieu, Blero et al. 2004, Duan, Liu et al. 2012). The question of why 20 
Nav1.9 deployment at the plasma membrane is relatively low under basal conditions 21 
was addressed in a recent study that compared key trafficking motifs in Nav1.9 with 22 
those in Nav1.7 (Sizova, Huang et al. 2020). Evidence for distinct trafficking signals 23 
between Nav1.9 and Nav1.7 fits well with our observations that the trafficking of Nav1.9 24 
(and Nav1.8), but not Nav1.7 to DRG cell plasma membrane can be upregulated by an 25 
ErbB1-dependent mechanism in neuropathic pain. The ErbB1-dependent trafficking 26 
of Nav1.9 (and Nav1.8) to key locations for neuronal excitability may be crucial to 27 
neuropathic hypersensitivity.  28 
We further demonstrated striking, ErbB1- and Akt-dependent trafficking of 29 
Cav1.2 to the plasma membrane and axon initial segment/proximal axon of small 30 
peripherin-positive DRG cells following CCI (Fig. 8C). This matches evidence for the 31 
preferential expression of Cav1.2 (together with known protein partners) in the soma, 32 
plasma membrane and axon initial segment/proximal axon of small, peripherin-33 
positive C-fibre afferents (Brandao, Dell'Acqua et al. 2012) and may, together with the 34 
well documented clustering of Nav channels in this region (Zhou, Lambert et al. 1998), 35 
contribute to increased excitability. Indeed, selective Cav1.2 blockers or Cav1.2 36 
knockdown produce analgesia in a number of chronic pain models (Vanegas and 37 
Schaible 2000, Yaksh 2006, Fossat, Dobremez et al. 2010) (Vanegas and Schaible, 38 
2000; Yaksh, 2006; Fossat, Dobremez et al., 2010). Furthermore, numerous reports 39 
describe growth factor-induced trafficking of channels (including TRP, KCa and both L- 40 
and N-type Ca2+ channels) to the plasma membrane in various cell types including 41 
neurons and the crucial role of PI 3-kinase/Akt signalling in this (Blair and Marshall 42 
1997, Kanzaki, Zhang et al. 1999, Bezzerides, Ramsey et al. 2004, Viard, Butcher et 43 
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al. 2004, Chae, Martin-Caraballo et al. 2005). In addition to the Akt-dependent 1 
targeting of the Rab-GAP AS160 and disinhibition of LRP1-associated trafficking 2 
identified here (as also identified in GLUT4 translocation (Leto and Saltiel 2012), 3 
trafficking of Cav1.2 and 2.2 has been shown to depend on both b and a2d channel 4 
subunits, the latter of which interact directly with LRP1 (Viard, Butcher et al. 2004, 5 
Hoppa, Lana et al. 2012, Kadurin, Rothwell et al. 2017, Nieto-Rostro, Ramgoolam et 6 
al. 2018). Nerve injury-induced trafficking of Cav1.2 to functionally important 7 
subcellular locations in DRG neurons, including the plasma membrane, proximal axon 8 
and potentially, even synaptic release sites (Hoppa, Lana et al. 2012) could play a 9 
crucial part in nociceptive hypersensitivity. Other channel-interacting proteins, such as 10 
CRMP2, are reported to modulate trafficking of channels, including Nav1.7 and Cav2.2 11 
(Brittain, Piekarz et al. 2009, Chi, Schmutzler et al. 2009, Chew and Khanna 2018).  12 
The pseudo-polar morphology of DRG neurons is thought to be responsible for 13 
an increased probability of action potential failure at the bifurcation, especially for high 14 
frequency firing (Luscher, Lipp et al. 1996, Nascimento, Mar et al. 2018). Peripheral 15 
nerve injury leads to a reduction in this low-pass filtering and may thereby contribute 16 
to neuropathic pain hypersensitivity (Gemes, Koopmeiners et al. 2013). Ion channel 17 
recruitment to a potential axon initial segment-like zone in the proximal stem axon and 18 
soma plasma membrane, particularly in small diameter DRG neurons, may thus exert 19 
an important influence over spike propagation (Nascimento, Mar et al. 2018). Both Na+ 20 
and Ca2+ currents contribute to action potentials in DRG cells (Kostyuk, Veselovsky et 21 
al. 1981, Heyer and Macdonald 1982) and intracellular Ca2+ levels may additionally 22 
facilitate spike propagation (Luscher, Lipp et al. 1996), so the nerve injury-associated 23 
translocation of Na+ and Ca2+ channels here could potentially play a part in enhanced 24 
action potential generation along the axon of nociceptors.  25 
Overall, the work presented here corroborates and provides a mechanistic 26 
basis for previous clinical observations in neuropathic pain patients. Increased 27 
recruitment of Nav1.9, Nav1.8 and Cav1.2 to the apical plasma membrane and proximal 28 
stem axon of primary afferent nociceptive neurons following nerve injury may be 29 
crucial to the increased excitability and excessive firing that is likely to underlie pain 30 
hypersensitivity. These events, in small diameter nociceptive DRG neurons, are driven 31 
by ErbB1, acting in synergy with ErbB2, and their downstream signalling through Akt 32 
to regulate vesicular trafficking, emphasizing the potential value of targeting ErbB1 33 
and ErbB2 to suppress these processes and achieve analgesia for neuropathic pain. 34 
 35 
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Figure Legends 13 
 14 
Figure 1: The highly selective ErbB1 inhibitor, erlotinib, reverses nerve injury-15 
induced hypersensitivity in reflex pain behaviours and increases a biomarker of 16 
cellular activation in nociceptors. A) - C) show time courses of reflex pain 17 
behaviours in the CCI neuropathic pain model, following administration of erlotinib 18 
(10mg/kg, ip). All values are shown as mean±SEM. A) shows effects on mechanical 19 
hypersensitivity (assessed by von Frey filament Paw Withdrawal Thresholds PWT, 20 
n=5). B) shows effects on noxious thermal hypersensitivity (assessed by Hargreaves’ 21 
infra-red test Paw Withdrawal Latencies PWL, n=5). C) shows effects on noxious cold 22 
hypersensitivity (seen as increased Suspended Paw Elevation Times from 4oC 23 
shallow water bath; n=4). Ipsilateral hypersensitivity was significantly reversed by 24 
erlotinib for 140-160min in each case; ††p<0.01 by One-Way Repeated Measures 25 
ANOVA with Dunnett’s post-hoc test, while no significant effects were observed on 26 
contralateral responses. D) shows immunofluorescence staining for an unbiased 27 
activity reporter (phospho-CaMKII (Thr286), reflecting increased intracellular Ca2+ 28 
concentrations) in DRG neurons from naïve and CCI animals, as well as the effect of 29 
treatment with erlotinib (10mg/kg, ip, 1 hr). Both typical immunofluorescence images 30 
and quantitative analysis show that phospho-CaMKII (Thr286) staining in peripherin-31 
positive (nociceptive) DRG neurons was increased following CCI and this was 32 
reversed by erlotinib (n=4 in each case). One-Way ANOVA with Tukey’s post-hoc test 33 
revealed a significant increase due to CCI (*p<0.05) and its significant reversal by 34 
erlotinib (†p<0.05). Scale bars represent 50µm. Typical numbers of positive cells 35 
counted per section were 197 for peripherin and 76 for phospho-CaMKII (Thr286).  36 
 37 
Figure 2: ErbB1 expression in DRG is limited to small, unmyelinated nociceptive 38 
neurons and colocalises with ErbB2, but not ErbB3 or ERbB4. A) shows typical 39 
images of immunofluorescence staining using a highly characterised ErbB1 antibody 40 
(mouse monoclonal [EGFR1], ab30) that does not cross-react with other ErbB family 41 
members, compared to peripherin (a marker of unmyelinated C-fibre nociceptors). 42 
Very high concurrence of staining was observed in DRG from either naïve or CCI 43 
animals. Numbers of positive cells counted per section were typically 134 for 44 
peripherin and 112 for ErbB1. Around 80% of peripherin-positive cells expressed 45 
 41 
ErbB1 in both naïve and CCI conditions and this result was corroborated with a 1 
second, similarly specific ErbB1 antibody (rabbit monoclonal [E235], ab32077). The n 2 
values were 18 and 4, respectively. B) shows typical images of staining for ErbB1 3 
versus the myelinated afferent marker, NF-200; the satellite glial cell marker, 4 
glutamine synthetase; and the microglial/invading macrophage marker, CD68. 5 
Minimal co-localisation with ErbB1 (<14%) was observed in each case, in DRG from 6 
either naïve or CCI animals. Numbers of positive cells counted per section were 7 
typically 120 for ErbB1, 95 for NF-200, 182 for glutamine synthetase, and 66 for CD68, 8 
n=4 in each case. C) shows typical examples of staining using highly characterised 9 
antibodies (that do not cross-react with other ErbB family members) for ErbB2 (rabbit 10 
polyclonal, 06-562), ErbB3 (mouse monoclonal, H3.105.5) and ErbB4 (mouse 11 
monoclonal, H4.77.16) versus peripherin or ErbB1 (ab30). Abundant staining for 12 
ErbB2 was seen in a very high proportion (>90%) of peripherin-positive cells with little 13 
staining of other cells. There was a similarly high concurrence of ErbB2 staining with 14 
ErbB1, again limited to small DRG cells. ErbB2 was expressed in 93.9±1.0% and 15 
96.4±1.1% of ErbB1-positive cells from naïve and CCI DRG, respectively. Only 16 
occasional staining was observed for ErbB3 or ErbB4 in DRG and this was almost 17 
entirely associated with peripherin-negative cellular profiles. Less than 8% of 18 
peripherin-positive cells showed staining for ErbB3 or ErbB4. Numbers of positive cells 19 
counted per section were typically 191 for peripherin, 187 for ErbB1, 188 for ErbB2, 20 
11 for ErbB3, and 14 for ErbB4, n=4 in each case. Scale bars represent 50µm. 21 
 22 
Figure 3: ErbB2 inhibitors reverse nerve injury-induced mechanical 23 
hypersensitivity and act synergistically with selective ErbB1 inhibitors, 24 
matching evidence for direct ErbB1:ErbB2 interaction in small nociceptive DRG 25 
neurons. A) and B) show effects of the highly selective ErbB2 inhibitors, mubritinib 26 
(15mg/kg, ip) and tucatinib (15mg/kg, ip) in A), and the dual ErbB1/ErbB2 inhibitors, 27 
lapatinib (20mg/kg, ip) and afatinib (2.5mg/kg, ip) in B), on mechanical hypersensitivity 28 
following CCI, as assessed by von Frey filament PWT values (n=4-6). Ipsilateral 29 
hypersensitivity was significantly reversed for up to 140-180min in each case; †-30 
††p<0.05-0.01 by One-Way Repeated Measures ANOVA with Dunnett’s post-hoc 31 
test, while no significant effects were observed on contralateral responses. C) shows 32 
typical images from a Proximity Ligation Assay, with specific antibodies for ErbB1 33 
(ab30) and ErbB2 (06-562). Close target proximity is reported as orange fluorescence. 34 
Sections were counterstained for peripherin (green) using conventional 35 
immunofluorescence. Nerve injury induced a clear (>2-fold) increase in the percentage 36 
of peripherin-positive cells that showed ErbB1:ErbB2 proximity fluorescence 37 
compared to naïve. Typical numbers of positive cells counted per section were 117 for 38 
peripherin and 40 for ErbB1:ErbB2 proximity ligation, n=4 in each case. The statistical 39 
significance of changes was assessed by unpaired two-tailed t-test; **p<0.01, showing 40 
a significant CCI-induced increase in ErbB1:ErbB2 heterodimerisation compared to 41 
naïve. Scale bars represent 50µm. D) shows typical images of immunofluorescence 42 
staining for a prominent auto-/trans-phosphorylation site in ErbB2, phospho-ErbB2 43 
 42 
(Tyr1221/2), identified by a specific rabbit monoclonal antibody [6B12], compared to 1 
ErbB1, identified using ab30, in DRG from naïve, CCI and CCI animals treated with 2 
erlotinib, 10mg/kg ip, 1hr. The percentage of ErbB1-positive cells showing phospho-3 
ErbB2 (Tyr1221/2) staining was more than 2.5-fold increased following CCI and this 4 
was reversed by erlotinib. One-Way ANOVA with Tukey’s post-hoc test revealed a 5 
significant increase due to CCI (***p<0.01) and its significant reversal following 6 
erlotinib treatment (††p<0.01), n=4 in each case. Numbers of positive cells counted 7 
per section were typically 189 for ErbB1 and 53 for phospho-ErbB2 (Tyr1221/2). Scale 8 
bars represent 50µm. E) shows effects of selective ErbB1 and ErbB2 inhibitors, in 9 
combination, on mechanical hypersensitivity following CCI, as assessed by von Frey 10 
PWT scores. Low doses of erlotinib (0.33mg/kg, ip) and mubritinib (1.0mg/kg, ip), 11 
selected to produce just discernible levels of analgesia alone, were tested in 12 
combination. One-Way Repeated Measures ANOVA with Dunnett’s post-hoc test 13 
indicated statistically significant attenuation due to erlotinib at 20 and 40min following 14 
administration, for mubritinib at 20min and for the combination throughout the 20-15 
100min period; ††p<0.01; n=4 in each case. F) shows formal assessment of analgesic 16 
synergy between mubritinib (1.0mg/kg, ip) and erlotinib across a range of erlotinib 17 
doses (ip), using Bliss Additivism effect-based modelling to predict expected 18 
combination outcomes. Comparison of observed versus expected combination dose-19 
response curves by Extra Sum of Squares F test indicated a significant difference, 20 
reflected in a more than 3.8-fold reduction in EC50 value (mean [95% CI] from 1.09 21 
[1.06/1.14]) to 0.28 [0.25/0.31]mg/kg, †††p<0.001 (n=4-5 for each point).  G) shows 22 
the effects of individual and combined treatment with further (structurally distinct) 23 
selective ErbB1 and ErbB2 blockers, falnidamol (0.33mg/kg, ip) and tucatinib 24 
(1.0mg/kg, ip), respectively, against nerve injury-induced hypersensitivity. The 25 
observed analgesic effect was significantly greater than the predicted combination 26 
effect according to Bliss Additivism modelling (p<0.001, Student’s t-test, n=4). 27 
 28 
Figure 4: Nerve injury-induced mechanical hypersensitivity involves Src-29 
mediated transactivation of ErbB1 in small nociceptive DRG neurons. A) shows 30 
effects of the selective Src/Abl inhibitor, dasatinib (3mg/kg, ip) and the highly selective 31 
Src inhibitor, A419259 (15mg/kg, ip) on mechanical hypersensitivity following CCI, as 32 
assessed by von Frey filament PWT scores (n=4 in each case). Ipsilateral 33 
hypersensitivity was significantly reversed for 60min and 50min, respectively, with 34 
complete reversal at peak in both cases; ††p<0.01 by One-Way Repeated Measures 35 
ANOVA with Dunnett’s post-hoc test. No significant changes were seen in 36 
contralateral responses. B) shows typical images of immunofluorescence staining for 37 
phospho-Src (Tyr527); a site targeted by Csk that constitutively suppresses Src 38 
activity (using a specific rabbit polyclonal antibody) versus ErbB1 (identified using 39 
ab30). Staining for phospho-Src (Tyr527) was observed in a clear majority of ErbB1-40 
positive DRG cells in naïve animals, but this was approximately halved following CCI 41 
and the change was unaffected by erlotinib treatment (10mg/kg ip, 1hr). The statistical 42 
significance of changes was assessed by One-Way ANOVA with Tukey’s post-hoc 43 
 43 
test; **p<0.01 compared to naïve, n=4 in each case. Numbers of positive cells counted 1 
per section were 197 for ErbB1 and 47 for phospho-Src (Tyr527). Src activation by 2 
dephosphorylation at Tyr527 during CCI appeared to be independent of ErbB1 3 
functional activity. C) shows typical examples of staining for phospho-ErbB1(Tyr845); 4 
a site prominently targeted by Src (using a specific mouse monoclonal antibody, clone 5 
12A3) versus peripherin. Staining for phospho-ErbB1 (Tyr845) in peripherin-positive 6 
DRG cells was increased almost 3-fold following CCI, compared to that in naïve 7 
animals, but this was virtually unaltered following erlotinib (10mg/kg ip, 1hr), despite 8 
being completely reversed following dasatinib (3mg/kg ip, 1hr). The statistical 9 
significance of changes was assessed by One-Way ANOVA with Tukey’s post-hoc 10 
test. **p<0.01, increase compared to naïve and ††p<0.01, decrease compared to CCI, 11 
n=4 in each case. Numbers of positive cells counted per section were typically 231 for 12 
peripherin and 105 for phospho-ErbB1(Tyr845). Nerve injury clearly increased ErbB1 13 
phosphorylation at Tyr845 (the target site for upstream Src), and correspondingly, this 14 
was reversed by dasatanib, but not by erlotinib, indicating that the event was not 15 
downstream of ErbB1 activation. Scale bars represent 50µm in each case. 16 
 17 
Figure 5: Nerve injury induces autophosphorylation of ErbB1 at Tyr1068 with an 18 
intracellular peri-nuclear localisation and recruitment of Gab1, a linker to PI 3-19 
kinase/Akt signalling. A) shows typical images of dual immunofluorescence staining 20 
for phospho-ErbB1 (Tyr1068), an auto-/trans-phosphorylation site responsible for 21 
recruiting the signalling adapters Grb2 and Gab1 (using a specific rabbit monoclonal 22 
antibody [D7A5] versus ErbB1 (identified using ab30), in DRG from naïve, CCI and 23 
CCI animals treated with erlotinib (10mg/kg ip, 1hr) or dasatinib (3mg/kg ip, 1hr). The 24 
percentage of ErbB1-positive cells showing phospho-ErbB1 (Tyr1068) staining was 25 
clearly increased following CCI and this was fully reversed by erlotinib or dasatinib. 26 
One-Way ANOVA with Tukey’s post-hoc test revealed a significant increase due to 27 
CCI (*p<0.05) and its significant reversal following erlotinib or dasatinib (††p<0.01 and 28 
†p<0.05, respectively), n=4 in each case. Numbers of positive cells counted per 29 
section were typically 62 for ErbB1, and 36 for phospho-ErbB1(Tyr1068). B) shows 30 
cellular transect analysis of high power individual DRG cell images to reveal the 31 
intracellular localisation of the increased phosphorylation of ErbB1 at Tyr1068 32 
following nerve injury and the effect of erlotinib. Scale bar represents 5µm. A transect 33 
from the nuclear perimeter to the neuronal apex of each cell (identified in yellow in this 34 
example) was divided into 50 equal bins and the fluorescence intensity was recorded 35 
at each. The graph shows mean±SEM fluorescence intensity values plotted against 36 
bin number for typical individual DRG cells (n=8 in each case). The statistical 37 
significance of changes was assessed by Two-Way Repeated Measures ANOVA with 38 
Bonferroni’s post-hoc test; *-***p<0.05-p<0.001 for CCI compared to naïve; †-39 
†††p<0.05-p<0.001 for CCI plus erlotinib compared to CCI alone. Low basal levels of 40 
phospho-ErbB1 (Tyr1068) immunofluorescence were observed across the transects. 41 
Nerve injury induced a marked increase in ErbB1 phosphorylation at Tyr1068 at a 42 
perinuclear (not plasma membrane) location and this increment was fully reversed by 43 
 44 
erlotinib treatment, consistent with ErbB1 activation occurring here via a ligand-1 
independent intracellular process. C) shows typical images of a Proximity Ligation 2 
Assay, with specific antibodies for ErbB1 (ab30) and Gab1 (rabbit polyclonal, 06-579), 3 
reporting proximity as orange fluorescence. Sections were counterstained for 4 
peripherin (green) using conventional immunofluorescence. Nerve injury induced a 5 
clear increase in the percentage of peripherin-positive cells that showed ErbB1:Gab1 6 
proximity fluorescence compared to naïve and this was reversed by erlotinib (10mg/kg 7 
ip, 1hr) or mubritinib (15mg/kg ip, 1hr). Scale bar represents 50µm. Numbers of 8 
positive cells counted per section were typically 126 for peripherin and 42 for 9 
ErbB1:Gab1 proximity ligation, n=4 in each case. The statistical significance of 10 
changes was assessed by One-Way ANOVA with Tukey’s post-hoc test; *p<0.05 11 
showing a significant CCI-induced increase in Gab1 recruitment to ErbB1 compared 12 
to naïve, and †p<0.05 showing significant reversal.  13 
  14 
Figure 6: ErbB1-mediated activation of Akt following nerve injury and reversal 15 
of mechanical hypersensitivity by highly selective Akt inhibitors. A) shows typical 16 
images of immunofluorescence staining for phospho-Akt (Ser473); a phosphorylation 17 
site reflecting its activation (using a specific rabbit monoclonal antibody [EP2109Y]) 18 
versus ErbB1 (identified using ab30), in DRG from naïve, CCI and CCI animals treated 19 
with erlotinib (10mg/kg ip, 1hr), the Akt inhibitor, ipatasertib (20mg/kg ip, 1hr) or the 20 
Src inhibitor, dasatinib (3mg/kg ip, 1hr). The percentage of ErbB1-positive cells 21 
showing phospho-Akt (Ser473) staining was clearly increased following CCI and this 22 
was reversed by erlotinib, ipatasertib or dasatinib. One-Way ANOVA with Tukey’s 23 
post-hoc test revealed a significant increase due to CCI (*p<0.05) and its significant 24 
reversal following erlotinib, ipatasertib or dasatinib (††p<0.01 or †p<0.05), n=4 in each 25 
case. Scale bar represents 50µm. Numbers of positive cells counted per section were 26 
typically 140 for ErbB1, and 74 for phospho-Akt (Ser473). B) shows effects of the 27 
selective Akt inhibitors, ipatasertib (20mg/kg ip) and afuresertib (3.3mg/kg ip) on 28 
mechanical hypersensitivity following CCI, as assessed by von Frey filament PWT 29 
scores (n=6 and 5, respectively). Ipsilateral hypersensitivity was significantly reversed 30 
for 160 and 180min, respectively, with complete reversal at peak in both cases; 31 
††p<0.01 by One-Way Repeated Measures ANOVA with Dunnett’s post-hoc test. No 32 
significant changes were seen in contralateral responses.  33 
 34 
Figure 7: Nerve injury induces ErbB1-, ErbB2- and Akt-dependent intracellular 35 
phosphorylation of the vesicular trafficking regulator, AS160 and translocation 36 
of the AS160 partner (and vesicular chaperone) LRP1. A) shows typical images of 37 
immunofluorescence staining for phospho-AS160 (Thr642), an Akt-target site 38 
reflecting AS160 inhibition, which terminates its vesicular anchoring role (using a 39 
specific rabbit polyclonal antibody, BS4293) versus ErbB1 (identified using ab30), in 40 
DRG from naïve, CCI and CCI animals treated with erlotinib (10mg/kg ip, 1hr) or 41 
ipatasertib (20mg/kg ip, 1hr). The percentage of ErbB1-positive cells showing 42 
phospho-AS160 (Thr642) staining was clearly increased following CCI and this was 43 
 45 
reversed by erlotinib or ipatasertib. One-Way ANOVA with Tukey’s post-hoc test 1 
revealed a significant increase due to CCI (***p<0.001) and its significant reversal 2 
following erlotinib (††p<0.01) or ipatasertib (†p<0.05), n=4 in each case. Scale bar 3 
represents 50µm. Numbers of positive cells counted per section were typically 115 for 4 
ErbB1, and 79 for phospho-AS160 (Thr642). B) shows cellular transect analysis of 5 
high power individual DRG cell images to reveal the subcellular localisation of the 6 
increased phosphorylation of AS160 at Thr642 following nerve injury and the effect of 7 
treatment with erlotinib, mubritinib (15mg/kg ip, 1hr) or ipatasertib. Scale bar 8 
represents 5µm. A transect from the nuclear perimeter to the neuronal apex was 9 
constructed for each cell, the proximal part divided into 50 equal bins to encompass 10 
all discernible phospho-AS160 (Thr642) staining (0.09µm per bin), and the 11 
mean±SEM fluorescence intensity recorded at each. This was plotted against distance 12 
from the nuclear perimeter (n=8 in each case). The statistical significance of changes 13 
was assessed by Two-Way Repeated Measures ANOVA with Bonferroni’s post-hoc 14 
test; *-***p<0.05-p<0.001 for CCI compared to naïve and †-†††p<0.05-p<0.001 for 15 
CCI plus erlotinib, mubritinib or ipatasertib compared to CCI alone. In basal conditions 16 
a low level of phospho-AS160 (Thr642) staining was observed in a ring-like 17 
configuration close to the nuclear perimeter. Nerve injury induced a striking (3-fold at 18 
peak) increase in phospho-AS160 (Thr642) fluorescence, concentrated at a slightly 19 
more distal (but still perinuclear) site compared to naïve, and this change was reversed 20 
by erlotinib, mubritinib or ipatasertib. C) shows cellular transect analysis of high power 21 
individual DRG cell images to reveal the intracellular localisation of LRP1 (using a 22 
specific rabbit monoclonal antibody, [EPR3724], versus ErbB1 (identified using ab30), 23 
following nerve injury and the effect of erlotinib or ipatasertib. Scale bar represents 24 
5µm. A transect from the nuclear perimeter to the neuronal apex was divided into 50 25 
equally spaced bins and the fluorescence intensity was recorded at each, for typical 26 
individual DRG cells in naïve, CCI and CCI plus erlotinib or CCI plus ipatasertib 27 
animals, and the mean ± SEM intensity values plotted against bin number (n=9 in each 28 
case). The statistical significance of changes was assessed by Two-Way Repeated 29 
Measures ANOVA with Bonferroni’s post-hoc test; *p<0.05 for CCI compared to naïve; 30 
†p<0.05 for CCI plus erlotinib compared to CCI, and †-††p<0.05-p<0.01 for CCI plus 31 
ipatasertib compared to CCI. In basal conditions, scattered clusters of LRP1 32 
fluorescence were seen in a broadly perinuclear location. Nerve injury induced the 33 
significant appearance of LRP1 clusters in more distal parts of the transect and this 34 
change was reversed by treatment with selective ErbB1 or Akt inhibitors.  35 
 36 
Figure 8: Nerve injury induces ErbB1- and Akt-dependent trafficking of Nav1.9 37 
(an LRP1 partner) and Cav1.2 to the plasma membrane of small DRG neurons. 38 
A) shows cellular transect analysis of high power individual DRG cell images to reveal 39 
the subcellular localisation of Nav1.9 (using a specific guinea pig polyclonal antibody, 40 
AGP-030) in ErbB1-positive DRG cells (identified using ab30) from naïve, CCI and 41 
CCI animals treated with erlotinib (10mg/kg ip, 1hr) or ipatasertib (20mg/kg ip, 1hr). 42 
Scale bar represents 5µm. The cyan (ErbB1) channel is omitted to enhance clarity of 43 
 46 
Nav1.9 distribution. A transect from the nuclear perimeter to the neuronal apex was 1 
divided into 50 equal bins and the mean±SEM fluorescence intensity was recorded at 2 
each (n=8). The statistical significance of changes was assessed by Two-Way 3 
Repeated Measures ANOVA with Bonferroni’s post-hoc test; **-***p<0.01-p<0.001 for 4 
CCI compared to naïve and †-†††p<0.05-p<0.001 for CCI plus erlotinib or ipatasertib 5 
compared to CCI alone. In basal conditions Nav1.9 appeared to be distributed quite 6 
uniformly across the transect but following nerve injury there was clearly increased 7 
deployment to the plasma membrane or nearby. This CCI-induced relocation of Nav1.9 8 
was fully reversed by treatment with erlotinib or ipatasertib. B) shows typical images 9 
of a Proximity Ligation Assay, with specific antibodies for Nav1.9 (rabbit polyclonal 10 
ASC-017) and LRP1 (mouse monoclonal [5A6]). Close target proximity is reported as 11 
orange fluorescence. Sections were counterstained for peripherin (green) using 12 
conventional immunofluorescence, n=4 in each case. One-Way ANOVA with Tukey’s 13 
post-hoc test revealed a significant increase due to CCI (*p<0.05) and reversal by 14 
erlotinib treatment (†p<0.05). These results clearly indicate Nav1.9 association with 15 
LRP1 and its translocation to the proximity of the plasma membrane following CCI 16 
through an ErbB1-dependent process. C) shows cellular transect analysis of high 17 
power individual DRG cell images to reveal the intracellular localisation of Cav1.2 18 
(using a specific guinea pig polyclonal antibody, AGP-001) versus ErbB1 (identified 19 
using ab30), following nerve injury and the effect of treatment with erlotinib or 20 
ipatasertib. Scale bar represents 5µm. A transect from the nuclear perimeter to the 21 
neuronal apex was divided into 50 bins and the fluorescence intensity was recorded 22 
at each, with matched extension beyond the 50th bin at the plasma membrane, where 23 
appropriate. Mean±SEM intensity was plotted against bin number for typical DRG cells 24 
from naïve, CCI and CCI plus erlotinib or CCI plus ipatasertib animals (n=8 in each 25 
case). The statistical significance of changes was assessed by Two-Way Repeated 26 
Measures ANOVA with Bonferroni’s post-hoc test; **p<0.01-p<0.001 for CCI 27 
compared to naïve and †-†††p<0.05-p<0.001 for CCI plus erlotinib or CCI plus 28 
ipatasertib compared to CCI. In basal conditions Cav1.2 fluorescence was expressed 29 
broadly but moderately concentrated near plasma membrane. Nerve injury induced a 30 
marked and significant increase in Cav1.2 deployment at the plasma membrane and 31 
beyond into proximal regions of the AIS and axon itself. These changes were reversed 32 
by treatment with erlotinib or ipatasertib.  33 
 34 
Supplementary Figure: CCI nerve injury induces ErbB1-dependent trafficking 35 
of Nav1.8, but not Nav1.7 to the plasma membrane of small DRG neurons. The 36 
Figure shows cellular transect analysis of high power individual DRG cell images to 37 
reveal the subcellular localisation of Nav1.8 and Nav1.7 (using specific rabbit 38 
polyclonal antibodies, ASC-016 and ASC-007, respectively) in ErbB1-positive DRG 39 
cells (identified using ab30) from naïve, CCI and CCI animals treated with erlotinib 40 
(10mg/kg, ip, 1hr). A transect from the nuclear perimeter to the neuronal apex was 41 
divided into 50 equal bins and the mean±SEM fluorescence intensity was recorded 42 
at each (n=9 and 6, respectively). The statistical significance of changes was 43 
 47 
assessed by Two-Way Repeated Measures ANOVA with Bonferroni’s post-hoc test; 1 
*-**p<0.05-p<0.01 for CCI compared to naïve and †p<0.05 for CCI plus erlotinib 2 
compared to CCI alone. In basal conditions, Nav1.8 and Nav1.7 appeared to be 3 
distributed quite uniformly across the transect but following nerve injury there was 4 
significant deployment of Nav1.8 (although not Nav1.7) to the plasma membrane or 5 













































Table 1: Primary antibodies used. 1 
   Target       Antibody          Supplier; ID (dilution) 
ErbB1 EGF-binding domain  
ErbB1 cytoplasmic domain 
ErbB1 cytoplasmic domain 
mouse monoclonal [EGFR1] * 
rabbit monoclonal [E235] * 
mouse monoclonal [8G6.2] 
Abcam; ab30 (1:1000) 
Abcam; ab32077 (1:2000) 
Merck Millipore; 05-1047 (1:1000) 
ErbB2 
 
rabbit polyclonal **        
rabbit monoclonal **          
Merck Millipore; 06-562 (1:1000) 
Origene; UMAB36 (1:250) 
ErbB3 mouse monoclonal [H3.105.5] † ThermoFisher; MA5-13008 (1:2000) 
ErbB4 mouse monoclonal [H4.77.16] †† ThermoFisher; MA5-12888 (1:1000) 
peripherin chicken polyclonal           Abcam; ab39374 (1:7500) 
NF-200 chicken polyclonal           Merck Millipore; AB5539 (1:15000) 
glutamine synthetase rabbit polyclonal           Abcam; ab49873 (1:8000) 
CD68 mouse monoclonal [ED1] Abcam; ab31630 (1:500) 
TRPV1 guinea pig polyclonal        Abcam; ab10295 (1:3000) 
phospho-CaMKII (Thr286) rabbit polyclonal           BioWorld Technology Inc; BS5009 (1:2000) 
phospho-Src (Tyr527) rabbit polyclonal           
 
Cell Signaling Technology; 2105 (1:100) 
phospho-ErbB1 (Tyr845) mouse monoclonal [12A3] Merck Millipore; 04-283 (1:1000) 
 
phospho-ErbB1 (Tyr1068) rabbit monoclonal [D7A5] Cell Signaling Technology; 3777 (1:250) 
phospho-ErbB2 (Tyr1221/1222) rabbit monoclonal [6B12] Cell Signaling Technology; 2243 (1:200) 
phospho-Akt (Ser473) rabbit monoclonal [EP2109Y] Abcam; ab81283 (1:400) 
phospho-ERK (Thr202/Tyr204) rabbit monoclonal [D13.14.4E] Cell Signaling Technology; 4370 (1:250) 
phospho-AS160 (Thr642) rabbit polyclonal  BioWorld Technology Inc; BS4293 (1:420) 
pan-AS160 rabbit polyclonal Merck Millipore; ABS-54 (1:2000) 
Gab1 rabbit polyclonal  Merck Millipore; 06-579 (1:2000) 
LRP1 rabbit monoclonal [EPR3724] 
mouse monoclonal [5A6] 
Abcam; ab92544 (1:3000) 
Abcam; ab28320 (1:1250) 
Nav1.7 rabbit polyclonal Alomone; ASC-008 (1:1000) 
Nav1.8 rabbit polyclonal Alomone; ASC-016 (1:1000) 
Nav1.9 guinea pig polyclonal 
rabbit polyclonal 
Alomone; AGP-030 (1:2000) 
Alomone; ASC-017 (1:3000) 
Cav1.2 guinea pig polyclonal Alomone; AGP-001 (1:6000) 
 49 
ErbB1: *no cross reaction with ErbB2, 3, 4; ErbB2: **no cross reaction with ErbB1, 3, 4; ErbB3: †no 1 
cross reaction with ErbB1, 2, 4; ErbB4: ††no cross reaction with ErbB1, 2, 3. 2 







Table 2: Effects of intraperitoneal injection of a variety of highly selective ErbB1 6 
inhibitors on CCI-induced hypersensitivity in the von Frey Paw Withdrawal 7 
Threshold test.  8 
 9 
 10 
Experiments were carried out in animals that displayed marked ipsilateral 11 
hypersensitivity to von Frey filaments following CCI carried out 8-12 days previously. 12 
Drugs were injected (in 0.2ml per animal) under light isoflurane anaesthesia and after 13 
a 20min delay for recovery, Paw Withdrawal Threshold (PWT) testing was carried out 14 
at 20min intervals up to 3hr post-injection. The percentage reversal of hypersensitivity 15 
(ipsilateral compared to contralateral pre-drug PWT) was meaned over 20-140min 16 
post-drug administration. A range of highly selective ErbB1 inhibitors showed robust 17 
reversal of hypersensitivity, displaying both concentration-dependence and efficacy 18 
from structurally diverse agents. ** indicates significant reversal of hypersensitivity 19 
(One-Way ANOVA with Dunnett’s post-hoc test or Student’s t-test, as appropriate). No 20 
significant changes in contralateral PWT were observed for any of the drugs or on 21 









Dose; mg/kg (n) Mean % reversal of injury-
induced reduction in PWT 
(20-140 min post drug) 
erlotinib quinazoline 0.10 (4) 
0.33 (4) 
1.0 (4) 
3.3 (4)  
10 (5) 
3.7 ± 1.0 
9.9 ± 3.1 
    42.3 ± 10.3 ** 
 73.2 ± 6.5 ** 
 92.2 ± 4.0 ** 
gefitinib quinazoline 10 (4)  98.8 ± 4.5 ** 





10 (4)  83.9 ± 7.6 ** 
EGFRi 324674 4,6-substituted 
pyrimidine  
40 (4)  76.3 ± 8.5 ** 





Table 3: Effects of intraplantar injection of selective ErbB-receptor-targeting 4 
drugs on CCI-induced hypersensitivity in the von Frey Paw Withdrawal 5 
Threshold test.  6 
 7 
 8 
Experiments were carried out 8-12 days following CCI in animals that displayed 9 
marked ipsilateral hypersensitivity to von Frey filaments. Drugs were injected 10 
intraplantarly into the interdigital skin (in 50µl per animal) under light isoflurane 11 
anaesthesia, and Paw Withdrawal Threshold (PWT) testing recommenced after a 12 
20min delay for recovery and then repeated at 10min intervals up to 70min post-13 
injection. The mean percentage reduction in PWT score over 20-40min post-drug 14 
administration was calculated and the statistical significance of changes in ipsilateral 15 
or contralateral PWT scores was assessed by One-Way ANOVA with Dunnett’s post-16 
hoc test. Injection of EGF (100ng) ipsilateral to CCI caused significant exacerbation of 17 
injury-induced hypersensitivity (**p<0.01) from 20-40min following administration. This 18 
effect was reversed by co-injection of the ErbB1 inhibitor, erlotinib (2.2ng) or the ErbB2 19 
inhibitor, mubritinib (7.0ng), which had no discernible effects alone. The ErbB3/4-20 
selective agonist, neuregulin1-b1 EGF domain (NRG1, (100ng) did not mimic the 21 
effect of EGF. Contralateral injection of EGF or NRG1 had no effect on ipsilateral PWT 22 
values in CCI animals. Either ipsilateral or contralateral injection of EGF had no effect 23 
on contralateral PWT values in CCI animals and was also without effect on baseline 24 
PWT values in naïve controls. Administration of vehicle alone had no discernible 25 
effect.   26 
 27 
Condition Intraplantar drug 
(hindlimb side of 
administration 
relative to nerve 
injury; n) 
Mean % reduction in PWT 
score 20-40 min post-drug 
(ipsilateral) 
Mean % reduction in 
PWT score 20-40 min 
post-drug (contralateral) 
naive EGF (4) 
vehicle (4)  
                -1.9 ± 8.1 
 5.4 ± 7.9 
- 
- 
CCI   
 
EGF (contra; 6) 
EGF (ipsi; 6) 
EGF + erlotinib  
(ipsi; 6) 
EGF + mubritinib 
(ipsi; 5) 
vehicle (ipsi; 4) 
 -8.4 ± 14.5 
    48.1 ± 14.0 ** 
-3.4 ± 8.3 
   7.6 ± 13.7 
 3.9 ± 6.1 
-1.0 ± 10.1  






NRG1 (contra; 4) 
NRG1 (ipsi; 4) 
  -7.0 ± 13.4  




















































































































































































































































































































































































Supplementary Figure 1 
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